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Abstract 
TITRATING AND EVALUATING MULTIPLE DRUG REGIMENS 
WITHIN SUBECTS 
By Margaret Shih, Bachelor of Science at the University of California at Berkeley 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor 
of Philosophy at Virginia Commonwealth University. 
Virginia Commonwealth University, 2001 
Research Directors: Dr. Walter H. Carter, Jr., Chairman, Department of Biostatistics 
Dr. Chris Gennings, Associate Professor, Department of Biostatistics 
The dosing of combination therapies is commonly undertaken empirically by prac-
ticing physicians, and there is a lack of a coherent algorithm to approach the problem of 
combination dosing. Current methods of evaluating multiple drug combinations in clini-
cal trials generally do not provide information regarding the location of more effective 
dosages when the combination is not found to differ from the standard, even though the 
absence of a difference does not necessarily mean the new combination is ineffective. 
Additionally, if a new combination is found to be more effective, often a large proportion 
of the subjects has not benefited from the trial. This may lead to problems with patient 
enrollment and adherence to the study protocol, and even with early stopping rules, the 
time patients spend on inferior treatments may have lasting detrimental effects. This 
XI 
paper describes an evolutionary operation (EVOP) direct-search procedure to titrate com-
bination doses within individual patients . The Nelder-Mead simplex direct-search method 
is used to titrate a combination of drugs within individual subjects. Desirability functions 
are incorporated to define the main response of interest and additional responses or con-
straints. Statistical methodology for determining whether the titrated treatment combina-
tion has resulted in an improvement in patient response and for evaluating whether a 
therapeutic synergism exists is developed. Inferences can be made about the efficacy of 
the combination or about the individual drugs that comprise the combination. This 
approach allows every patient the potential to benefit from the combination under study 
and permits the consideration of multiple endpoints simultaneously. 
Chapter 1 
Introduction 
1.1 Motivation 
I.I.I Combination Therapies and Clinical Practice 
The use of multiple medications in the treatment of individual patients is an increasingly 
commonplace occurrence. The elderly population, who consume the most drugs and in 
whom relative drug consumption continues to increase, is rapidly growing in the United 
States and other developed nations. The pace of new drug development, from drug dis-
covery to drug production, has accelerated greatly, and single diseases are now treated 
with multiple drugs targeting different biochemical pathways or different aspects in the 
pathophysiology of a disease. This increase in drug consumption brings with it a dramatic 
increase in the potential for drug interactions and adverse drug reactions. New approaches 
to treatment and prescribing are needed to address these increasingly complicated dosing 
regimens. 
Dose titration with single compounds is a relatively straightforward process 
employed by physicians to identify appropriate dose levels which produce improved 
responses in patients while simultaneously minimizing the adverse side effects a 
patient may experience. After taking into account a patient's age, weight, and other fac-
tors specific to the patient, the physician will prescribe an initial dose which may be 
increased or decreased as needed, depending on how the patient responds. This titration 
continues until a favorable balance between the desired response and undesirable side 
effects is achieved. 
2 
The difficulty arrives in attempting to translate this approach to determining dos-
ages in the case where multiple drugs are being prescribed in the treatment of a single disc 
ease, or where the consideration of multiple endpoints is needed in the case where a single 
treatment is prescribed. There is currently no systematic or efficient method for determin-
ing dosages in multi-drug regimens. The physician generally either chooses to address the 
problem empirically, or will employ an ad-hoc approach, varying the levels of one drug 
while keeping the doses of all the other drugs in the combination fixed. Unfortunately, 
this approach does not account for potential interactions among the drugs, which may be 
crucial when searching for the most desirable therapy. 
1.1.2 Combination Therapies and Clinical Trials 
Not only is combination dosing difficult for practicing physicians in the day-to-day care of 
their patients, but it also presents a problem in both clinical trials research and drug evalu-
ation research. Suppose we are evaluating a novel two-drug combination, which is com-
posed of a new therapy plus the standard therapy. A typical approach which may be used 
3 
is to randomize half of the subjects to the standard drug group and the other half to the 
two-drug combination. There are several problems with this approach. The first problem 
is that if no difference in response is found between the groups, this does not necessarily 
mean that the new combination is ineffective. The lack of effect may lie in the dose cho-
sen for use in the study. Secondly, this approach does not provide any information regard-
ing the location of more effective doses ifthe combination is not found to differ from the 
standard. On the other hand, if the new combination is found to be more effective, 
approximately half the subjects enrolled in the study, those randomized to the standard 
treatment, have not benefited from the trial. Finally, even with early stopping rules, the 
time a patient spends on the inferior treatment can have lasting detrimental effects. These 
problems can lead to difficulties with patient recruitment and adherence to the study pro-
tocol. 
1.1.3 Combination Therapies and Response Surface Methods 
Outside of the clinical trials arena, a common approach which has been used to evaluate 
combination therapies is the use of response surface methodology (RSM). With this 
approach, an experiment is carried out using a grid of fixed dose combinations. The fixed 
combinations are administered to subjects, often using a factorial design, and the response 
is observed over the range of dose combinations. The resulting response surface can then 
be used to identify areas of improved response. This is an effective approach, but one lim-
ited in its application by several aspects. Firstly, this approach requires the use ofprede-
4 
termined, fixed combinations, none of which may actually correspond to the best 
treatment. Also, the ideal treatment may lie entirely outside of the range of doses used in 
the study. Furthermore, these studies quickly become expensive due to the numerous dose 
combinations required. Finally, RSM requires the pre-specification of the dose-response 
relationship, which is usually unknown. This requires an additional assumption that the 
dose-response relationship is well approximated by the equation specified. 
1.1.4 Research Objectives 
The goal of our research has been to develop a more systematic and efficient, yet practical 
and flexible, method for titrating combination therapies within individual patients and for 
evaluating the efficacy of multiple drug therapies. We have addressed the problem using 
an evolutionary operation (EVOP) approach and by incorporating desirability functions, 
both of which have been successfully applied in industrial settings but which until now 
have not seen much application in the field of medicine. The methodology described 
allows each subject to benefit by receiving a personalized 'best' therapy. The titration is 
carried out using practical therapeutic units (e.g. whole pills) and permits the consider-
ation of multiple endpoints simultaneously. Finally, inferences can be made regarding 
therapeutic synergism and the efficacy of combination therapies without requiring the 
specification of either the dose-response relationship or distributional assumptions. 
1.2 Prospectus 
Chapter 2 is a literature review ofEVOP, EVOP direct-search methods, and desirability 
functions. Chapter 3 is written in the format of a paper submitted for journal publication 
and contains an overview of the mechanics of the titration process as well as a more 
detailed discussion of statistical inference and methodological issues. The figures and 
tables are provided at the end of the chapter. Chapter 4 contains a discussion of possible 
clinical applications ofEVOP direct-search methods and an example of a proposed study 
protocol employing this methodology in the titration of a two-drug combination therapy 
for the treatment of type 2 diabetes. Chapter 5 is a summary of the simulation studies 
which were conducted to examine the effectiveness of the multi-drug titration algorithm in 
combination dosing and the effects of the sample size, the number of steps, the shape of 
the desirability function, and the initial step size. Chapter 6 is a research summary. 
References for the sample study protocol are listed at the end of Chapter 4. All 
other references are listed in the main Reference section after Chapter 6. 
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Chapter 2 
Literature Review 
2.1 Evolutionary Operation (EVOP) 
The optimization of functions of multiple variables has always been of interest to statisti-
cians (Hotelling, 1941). Friedman and Savage (1947) proposed a sequential one-factor-at-
a-time optimization procedure, and Box and Wilson (1951) discussed the simultaneous 
optimization of multiple factors, which was the groundwork for the evolutionary operation 
procedure (EVOP) eventually introduced by Box in 1957. The EVOP technique has since 
been widely and successfully applied in the industrial setting, particularly in manufactur-
ing processes, where it is used as a method of increasing plant efficiency by increasing the 
rate at which improvements to production can be made. 
The evolutionary operation technique allows one to search for improved condi-
tions while a process is in production by observing the effects of small, deliberate changes 
in the operating conditions which result in a type of forced or artificial evolutionary pro-
cess. Traditional applications of EV OP have involved the use of factorial designs (Fisher, 
1935; Yates, 1935; D.R. Cox, 1958; and Snedecor and Cochran, 1980) to introduce varia-
tions in the operating conditions. EVOP utilizes information from the process itself to 
6 
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make improvements to the resulting product and has proven useful in optimizing multidi-
mensional relationships without requiring specification of either a model or distribution 
(Box, 1957; Box and Draper, 1969; Spendley, Hext, and Himsworth, 1962). 
Whereas response surface methods are a static research technique, evolutionary 
operation can be applied as a continuous and automatic production-line method. Hunter 
and Kittrell (1966) present an extensive review of various industrial applications of 
EVOP, most of which take place in the chemical industry, although applications in the 
automotive and food industries are also discussed. For a more detailed, in-depth discus-
sion ofEVOP techniques, one is referred to the text by Box and Draper (1969). 
As an example of how EVOP would work in practice, suppose we are trying to 
optimize the response of an ongoing industrial manufacturing process, and suppose the 
response to be optimized is the yield of chemical product. The yield of the product would 
be continuously monitored, as would the operating conditions, which might consist of the 
temperature, pressure, and amount of starting material. Minor variants in the operating 
conditions are then introduced in a factorial pattern. When a significant change in the 
yield is found in either a positive or negative direction, the operating conditions which 
produced the change in yield can be identified and subsequently adjusted in the direction 
of optimizing the yield. The monitoring process would then resume and could be contin-
ued indefinitely. 
Two of the most appealing aspects ofEVOP are the simplicity with which it can be 
carried out and the fact that it is conducted as an inherent part of a normal process, not as 
an artificially conducted experiment. The everyday application ofEVOP techniques does 
8 
not require the input of professional mathematicians or statisticians, and after the initial 
setup, the EVOP process can continue indefinitely, with new variables being added or old 
variables being removed at any time. 
There are several issues which arise in adapting EVOP, in its original form, to the 
problem of finding therapeutic treatment combinations which result in an improved out-
come status in individual patients. The first problem is that traditionally, EVOP requires 
the use of many design points. Use ofa factorial design would require the introduction of 
multiple small variations in treatment dosages which would be applied continuously to 
each patient. This presents obvious ethical problems regarding patient treatment, which 
overshadow other relatively minor issues of patient compliance and inefficiency in the 
design. 
A second problem arises from the traditional application of a statistical test of sig-
nificance to determine whether movement should be made to a new experimental region. 
Movement to a new dose region would not be made until there was statistical evidence 
that this would result in an improved patient response. In this case, the patient would be 
given multiple but varying doses of the drug combination within a limited dose range. 
The same set of doses would be repeatedly administered until there was evidence that 
changing the dose levels would benefit the patient. While it is appropriate that changes to 
the dose levels should not be made until there is some apparent benefit to be gained, this is 
again inefficient and results in a slower optimization process. 
An automatic EVOP procedure, which is more easily adapted to the clinical arena, 
was introduced by Spendley, Hext, and Himsworth (1962). Their sequential simplex 
9 
method, a modification of Box's original approach, is automatic, does not utilize a facto-
rial design, and does not require hypothesis testing before each movement. Instead, they 
use a direct search method approach to optimizing multiple factors. Direct search meth-
ods are a group of procedures also referred to as hill-climbing or steepest ascent proce-
dures, which are often used for minimizing or maximizing functions . Pre-specification of 
the dose-response relationship is not necessary, one is not limited to predetermined combi-
nations, and compounds can be added or removed from the combination under study at 
any time. 
This initial simplex EVOP method was later modified by Nelder and Mead 
(1965), who developed a more flexible method termed the Nelder-Mead Simplex proce-
dure. Their method has the advantage of allowing the simplex to accelerate and adapt to 
the contour to the response surface. Segreti (1977) has discussed the use of the Spendley, 
Hext, and Himsworth EVOP method in combination chemotherapy studies, and more 
recently, Berenbaum (1990) has discussed another modified approach, the partition 
method, in relation to the problem of optimizing cancer chemotherapy regimens in animal 
studies. Box also modified the procedure, creating complexes and incorporating con-
straints (1965). However, all of these applications refer to patients or animals randomized 
to a single treatment group and do not discuss dose optimization within individual 
patients. 
In our simulation studies, described in more detail in Chapter 5, we use the Nelder-
Mead Simplex algorithm to carry out the titration of combination therapies within each 
patient. While numerous other optimization methods, such as those listed in the previous 
10 
paragraphs could be applied, we elected to use the Nelder-Mead method because of its 
simplicity in application and the rapidity and efficiency with which it optimizes processes. 
2.2 Titration with the Nelder-Mead Simplex Procedure 
The Nelder-Mead procedure has been widely applied to a broad range of problems. In our 
simulations, the Nelder-Mead simplex algorithm was used to carry out the within-patient 
titration. The first step of the procedure is to establish an initial simplex, a geometric fig-
ure with a fixed number of vertices. In the p-dimensional case, where pis the number of 
variables being evaluated, the number of vertices required for the simplex is p+ 1. At each 
step, the simplex adapts its form, moving away from the vertex with the lowest response 
toward the direction of maximum response. 
This is most easily illustrated in the two-dimensional case where the simplex is a 
triangle. More specifically, if we are evaluating a two-drug combination, each vertex A, 
B, and C, of the triangle (Figure 2.1) would represent different dose levels of the combina-
tion. At the initial step, the subject's response is measured at each of these three dose 
combinations, and the composite desirability resulting from the administration of each 
combination is compared, with the simplex reflecting away from the least desirable 
response, through the centroid of the face created by the remaining vertices to a new point, 
E. In addition to reflection, the simplex can also extend, contract, or perform a shrinkage 
contraction, depending on the contour of the response surface. The possible cases are 
F 
N 
2 Q 
Drug 1 
Figure 2.1: Nelder-Mead simplex ABC with possible subsequent points (Table 2.1) 
listed in Table 2.1 and correspond to the diagram in Figure 2.1. 
The initial simplex step size, which specifies how far apart the initial vertices are, 
and the reflection and expansion coefficients used by the Nelder-Mead procedure, which 
Table 2.1: Conditions governing the formation of subsequent simplex. (Adapted from 
Olsson and Nelson, 1975) 
Condition Action New Simplex 
f(C) ~f(E) ~f(B) Reflect BCE 
f(E) <f(C) Extend BCF 
f(A) <f(E) Contract BCG 
f(B) <f(E) ~f(A) Contract BCH 
f(A) ~f(G) orf(E) ~f(H) Shrink A 'B'C 
11 
12 
determine how far the simplex can move or expand in one step, must be carefully speci-
fied by working with experts knowledgeable about the response and process variables 
being evaluated. Our application of the Nelder-Mead algorithm to within-patient titration 
is described in more detail in Chapter 3. 
2.3 Desirability Functions 
Desirability functions also address the problem of optimizing multiple responses simulta-
neously. However, while EVOP techniques focus on monitoring and optimizing the dif-
ferent operating conditions to optimize a single response, desirability functions are used to 
optimize multiple endpoints. The desirability function approach was first introduced by 
Harrington (1965) and later modified by Derringer and Suich (1980). Gibb (1998) further 
extended the methodology to desirability functions which are continuous and differentia-
ble. 
Desirability functions have been successfully applied in the industrial setting. 
Each endpoint of interest is transformed to a continuous desirability function, di, with val-
ues ranging from 0 to 1, where a value of 0 designates the response as not at all desirable, 
while a value of 1 is assigned to the most desirable response. The basic shape of the func-
tion is determined by whether one is trying to maximize or minimize the response, or aim 
for a range of target values. The exact shape of each desirability function is determined in 
collaboration with physicians or other experts knowledgeable about the disease under 
study and the therapeutic effects of the treatments being administered. 
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Gibb (1998) describes the use of both the normal cumulative distribution function 
and logistic cumulative distribution function in defining continuous desirability functions , 
but any function which maps the response to the (0,1) interval and which is continuous 
and differentiable could be used. In this study, a logistic cumulative distribution function 
was used. With the logistic function, the form of the 'bigger-is-better' or maximizing 
desirability function is 
[ (Y-a)]-1 di(m ax ) = 1 + exp- ~ , 
l 
where 
• 
Y; - Y;• • 
-~--, Y;• < Y;, and Y; E (0, 1). 
21nC-=~) 
Y; 
The parameter '1j is an average of the upper (Yi*) and lower (Yi*) bounds of the response 
level being targeted, bi controls the function spread, and Yi is such that d;( Y;.) = Y; and 
d/ Y;) = 1 - Y;. An example of a maximizing desirability function is given in Figure 2.2. 
1.0 
0.9 
0.8 
0.7 
0.6 
di ,max 0_5 
0.4 
0.3 
0.2 
0.1 
0.0 
14 
0 10 20 30 40 50 60 70 80 90 100 
y 
Figure 2.2: Example ofa maximizing desirability function. Yi*= 20, yi* = 40, Yi =0.05 . 
The 'smaller-is-better' or minimizing desirability, shown in Figure 2.3, is obtained 
1.0 
0.9 
0.8 
0.7 
di(min) 0·6 
0.5 
0.4 
0.3 
0.2 
0.1 
0.0 
0 10 20 30 40 50 60 70 80 90 100 
y 
Figure 2.3: Example ofa minimizing desirability function. Yi* = 60, Yi*= 80, Yi= 0.05. 
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simply by reversing the sign of the exponential argument, having the resulting form, 
[ ((Y -a))]-1 di(min) = 1 +exp 'b ' . 
l 
A target desirability function, shown in Figure 2.4, can then be constructed by multiplying 
a minimizing and a maximizing desirability such that di(tar) = di(max) x di(min) . This 
allows the researcher to incorporate asymmetry into the desirability function. The param-
eters ai, bi, and Yi, allow the researcher flexibility in defining the desirability function and 
the degree of conservativeness to incorporate. These individual desirability functions can 
1.0 
0.9 
0.8 
0.7 
di( tar) 0.6 
0.5 
0.4 
0.3 
0.2 
0.1 
0.0 
0 10 20 30 40 50 60 70 80 90 100 
y 
Figure 2.4: Example of a target desirability function. This function is the product of the 
maximizing desirability function, di(max)' shown in Figure 2.1, and the minimizing desir-
ability function, di(min)' shown in Figure 2.2. 
then be combined using the geometric mean to arrive at a single continuous measure of the 
overall composite desirability, D, such that D=( d 1 *d2 * ... *dk) Ilk_ 
16 
Derringer (1994) has also described the use of weights, in the specification of the 
desirability function, so that different responses can be assigned different levels of impor-
tance. Each response is weighted by an exponent, wi, so that the composite desirability 
with weights has the form 
D 
I I LW; (dw1dw2 dwk) . I · ·· k , 1 1, . . . , k. 
In our simulation studies, unweighted desirability functions are used. Specific examples 
of the application of desirability functions are detailed in Chapter 3. 
Chapter 3 
Titrating and Evaluating Multi-Drug Regimens within 
Subjects 
3.1 Introduction 
The use of multiple medications in the treatment of a single disease in an individual 
patient is an increasingly common occurrence. With single compounds, dose titration is 
relatively straightforward. Dose titration of single compounds is commonly employed by 
practicing physicians to find appropriate dose levels which produce improved responses in 
patients, or to maintain response levels as a disease progresses, while limiting the side 
effects a patient experiences. The physician, depending on a number of patient factors, 
chooses a starting dose which he or she may later increase or decrease incrementally 
depending on how the patient responds. Treatment changes continue to occur until a 
favorable balance between response and undesirable factors is achieved. However, this 
has never been extended for use in determining dosages in a multi-drug regimen and there 
is currently no accepted algorithm in use for combination titration. The physician gener-
ally approaches the problem empirically, or undertakes an ad hoc approach, where levels 
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of one drug are varied while the other drugs in the combination are kept fixed at a constant 
dose. Such an approach does not account for potential interactions among the drugs, 
which may be crucial when one is searching for the most desirable therapy. 
In this paper, we address the problem of titrating and evaluating multi-drug regi-
mens using an evolutionary operation (EVOP) approach to climb through the dose space 
to a location of improved patient response. EVOP techniques have been successfully 
applied in the industrial setting (Hunter and Kittrell, 1966), where they have proven useful 
in optimizing multidimensional relationships and do not require specification of either a 
model or distribution (Box, 1957; Box and Hunter, 1959; Box and Draper, 1969; Spend-
ley, Hext, and Himsworth, 1962). With EVOP, one searches for improved conditions 
while a process is in production by observing the effect of small changes in the environ-
ment or operating conditions. No movement is made toward a new experimental region 
until there is evidence the changes will result in an improved response. 
EVOP can be effectively adapted to the clinical setting where a combination of 
drugs is being used for treatment or being evaluated for efficacy. While the multidimen-
sional dose-response relationship is unknown, it can be observed at specific treatment 
combinations, and a predetermined algorithm can be followed to adjust the therapeutic 
doses toward improving patient outcome. For example, a patient may make periodic visits 
to a physician who monitors the patient for improvements in outcome in response to the 
multiple drugs being prescribed. The physician or researcher can use an EVOP direct 
search procedure to adjust the doses comprising the treatment combination in response to 
the patient's continuously evolving condition. The titration is carried out within each 
patient, allowing every patient to benefit from the therapy ifthere is any benefit obtain-
able. 
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Direct search methods are a group of procedures also referred to as hill-climbing 
or steepest ascent procedures, which are often used for minimizing or maximizing func-
tions. Using direct search methods allows compounds to be easily added or removed from 
the combination under study and does not require specification of distributional assump-
tions. There are several direct search algorithms that can be applied to the titration pro-
cess. The first automatic simplex EVOP algorithm was introduced by Spendley, Hext, and 
Himsworth in 1962. Nelder and Mead modified the procedure, adding the adaptive fea-
ture, which allows the simplex to conform to the characteristics of the response surface 
(Nelder and Mead, 1965). M.J. Box (1965) also modified the procedure, creating com-
plexes and incorporating constraints. Segreti (1977) has discussed the use of the Spend-
ley, Hext, and Himsworth EVOP method in combination chemotherapy studies, and more 
recently, Berenbaum (1990) has discussed another modified approach, the partition 
method, in relation to the problem of optimizing cancer chemotherapy regimens in animal 
studies. However, both of their approaches refer to patients or animals randomized to a 
single treatment group and do not discuss dose optimization within individual patients. 
In the current paper, the within-patient titration is described using the Nelder-
Mead algorithm, which is more flexible than the Spendley, Hext, and Himsworth method, 
permitting acceleration and adaptation to the response surface. In order to extend the flex-
ibility of this approach, we utilize a continuous desirability function (Gibb, 1998), which 
incorporates both the main response of interest and additional responses or constraints, as 
the overall measure of response. In this way, the main response or responses may be 
improved while simultaneously satisfying multiple additional constraints. 
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This paper describes an EVOP direct-search procedure to titrate doses within indi-
vidual patients. It also discusses statistical methodology useful for determining whether 
there has been an improvement in response and whether a therapeutic synergism exists 
among the drugs comprising a multi-drug regimen. 
3.2 Methods 
3.2.1 Desirability Functions 
The desirability function approach was developed by Harrington (1965) and later modi-
fied by Derringer and Suich (1980). Gibb (1998) extended the methodology to desirabil-
ity functions which are continuous and differentiable. Desirability functions have been 
successfully used in the industrial setting. Each response of interest is transformed to a 
continuous desirability function, d;, with values ranging from 0 to 1, where a value of 0 
designates the response as not at all desirable, while a value of 1 is assigned to the most 
desirable response. The index i represents the i1h desirability function or the i1h response 
of interest. The basic shape of the function is determined by whether one is trying to max-
imize or minimize the response, or aim for a range of target values. The exact shape of 
each desirability function is determined in collaboration with physicians or other experts 
knowledgeable about the disease under study and the therapeutic effects of the treatments 
being administered. 
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In this study, a logistic cumulative distribution function was used for the desirabil-
ity, but any function which maps the response to the (0, 1) interval and which is continuous 
and differentiable could be used. With the logistic function, the form of the 'bigger-is-bet-
ter' or maximizing desirability function (Gibb, 1998) is 
where 
[ ( Y- a)]-1 di(max) = 1 + exp- T , 
I 
y* - Y • 
--'(-1-_-y_,·.)-, Yi*< Y;, and Yi E (0, 1) . 
2ln --' 
Yi 
The parameter 3.j is an average of the upper (Yi*) and lower (Yi•) bounds of the response 
level being targeted, bi controls the function spread, and Yi is such that di(Y;.) = Yi and 
di(Y ;) = 1 - yi . The 'smaller-is-better' or minimizing desirability is obtained simply by 
reversing the sign of the exponential argument, having the resulting form, 
[ ( (Y - a ))]-1 di(min) = 1 + exp 'b ' . 
I 
A 'target' desirability function can then be constructed by multiplying a set of 
desirability functions, such as a minimizing desirability and a maximizing desirability to 
give di(target) = di(max) x di(min). This allows the researcher to incorporate asymmetry 
into the desirability function. The parameters ai, bi, and Yi allow the researcher flexibility 
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in defining the desirability function and the degree of conservativeness to incorporate. 
These individual desirability functions can then be combined using the geometric mean to 
arrive at a single continuous measure of the overall composite desirability, D, such that 
D=(d1 *d2* ... *diJ 11k. Derringer (1994) has also described the use of weights, in the speci-
fication of the desirability function, so that different responses can be assigned different 
levels of importance. Each response is weighted by an exponent, wi, so that the composite 
desirability with weights has the form 
1, . .. , k. 
In our simulation studies, we use unweighted desirability functions. 
As an example, consider the case where a physician is treating a type 2 diabetes 
patient with a combination of a sulfonylurea and metformin. There are numerous clinical 
endpoints the physician may monitor, including fasting plasma glucose (FPG), glycosy-
lated hemoglobin levels (HbA 1 c), the patient's lipid profile, weight, and blood pressure, 
and the number of adverse gastrointestinal and hypoglycemic events the patient experi-
ences. For any or all of these endpoints, a specific target, maximizing, or minimizing 
desirability function can be assigned and incorporated into the composite desirability 
function. Note that this method tends to weight small desirability values heavily so that if 
any of the individual desirabilities are small, the overall desirability remains small. 
As a simple case, suppose we only wish to monitor two endpoints, the patient's 
fasting plasma glucose (FPG) and the patient's body weight. Suppose we would like to 
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target the patient's FPG to be within the 80-140mg/dL range. Additionally, we want to 
minimize the increase in weight the patient may experience due to the treatment. Example 
desirability functions for each response are specified in Figure 3.1. 
Table 3.1 describes three cases which could occur. In Case 1, the patient has rea-
sonable fasting plasma glucose values and has experienced minimal weight gain. Refer-
ring to the desirability functions specified in Figure 3.1, the glucose value of 140 
corresponds to a desirability (d1) of0.95, and the weight gain of 10 corresponds to a desir-
ability (d2) of 1. This gives an overall desirability (D) of0.98. This high desirability sug-
gests that the patient is doing well with the current treatment. In the second case, the 
patient has a less desirable glucose value of 155, which corresponds to a desirability of 
0.19, and a weight gain of30 lbs, which corresponds to a desirability of0.5. This patient 
has an overall desirability of0.31, which indicates that changes to the patient's current 
therapeutic regimen may be needed to improve the treatment of this patient. The last 
example is of a patient with a high serum glucose value which is further outside the desir-
able limits, corresponding to a desirability of0.05, but one who has experienced no weight 
gain and so has a weight gain desirability of 1. Although this patient is doing well in 
terms of preventing weight gain, the glucose level is objectionably high, so the overall 
desirability decreases to 0.22. 
The application of desirability functions to within-patient titration can be useful 
for both the multiple drug case and the single agent case where multiple endpoints are 
being monitored. In the single agent case, desirability functions can provide the physician 
or researcher with a more objective way of evaluating the overall effect of a therapy and 
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can provide information about individual clinical endpoints and side effects. In the muli-
ple drug case, by combining desirability functions with EVOP direct-search methods, we 
can titrate combination therapies within individual subjects and make inferences about the 
efficacy of the combination. 
3.2.2 Titration Procedure 
Once the individual desirability functions are defined, they are incorporated into the over-
all composite desirability function, which becomes the response undergoing optimization 
during the titration process. In our simulations, the Nelder-Mead simplex algorithm was 
used to carry out the within-patient titration. The first step of the procedure is to establish 
an initial simplex, a geometric figure with a fixed number of vertices. In the p-dimen-
sional case, where p is the number of drugs comprising the combination under evaluation, 
the number of vertices required for the simplex is p+ 1. This is most easily illustrated in 
the two-dimensional case where the simplex is a triangle. Each vertex of the triangle rep-
resents different dose levels of the two-drug combination. At the initial step, the subject's 
response is measured at each of these three dose combinations, and the composite desir-
ability resulting from the administration of each combination is compared, with the sim-
plex reflecting away from the least desirable response, through the centroid of the face 
created by the remaining vertices to a new point. In addition to reflection, the simplex can 
also extend, contract, or perform a shrinkage contraction, depending on the contour of the 
response surface. 
The Nelder-Mead algorithm is run on a continuous scale, and therefore the new 
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dose combination determined by the algorithm is not given in units of whole pills or whole 
dose units. To enhance the practicability of the EVOP titration approach, the dose combi-
nations are adjusted to whole units (e.g. whole pills). The new dose combination to be 
administered is determined by either rounding to the nearest whole dose unit, or more con-
servatively, by rounding down to the dose unit. 
The initial simplex step size, which specifies how far apart the initial dose combi-
nations are, and the reflection and expansion coefficients used by the Nelder-Mead proce-
dure, which determine how far the simplex can move or expand in one step, are decided in 
collaboration with the physician expert, and can be modified to be more or less conserva-
tive depending on factors such as the therapeutic index of the drug involved. The step size 
of the initial simplex will depend on the potency and toxicity of the drugs under study, 
with smaller initial step sizes prudent for compounds of higher potency and/or toxicity. In 
the case where the drugs are already being used in combination in practice, a reasonable 
starting combination would be the number of pills or dose units with which the practicing 
physician generally initiates therapy. With a new and yet untested combination of drugs, 
where one cannot draw from previous experience, a more conservative approach is advis-
able. 
Each subject begins the process by being evaluated at each of the p+ 1 combina-
tions of p drugs in the regimen. The subject receives the initial combination and the 
response is recorded. The subject then receives the second combination, which is deter-
mined by the initial step size, and the response is measured after a time interval sufficient 
to preclude carryover effects. This continues for each of the p+ 1 drug combinations. It 
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should be noted that in the situation where there is a lengthy time to response, EVOP may 
not be practical due to the time required in setting up the initial simplex. After the initial 
simplex is established, the new simplex is formed, determining the next dose combination 
to be administered. This process repeats until the subject has passed through a fixed num-
her of steps or until other specific stopping criteria are reached and further titration is 
deemed unnecessary. The simplex movement can be continuously monitored by the phy-
sician, and the reflection, expansion, and contraction coefficients can be modified ifthe 
simplex expands to a dose with which physician is uncomfortable. Otherwise, a dose con-
straint can be put in as a boundary to prevent the simplex from moving above a certain 
dose in one or more dimensions. At the final step, the last simplex is evaluated and the 
combination producing the most desirable response is determined to be the 'best' treat-
ment combination. Possible stopping criteria include running the process until conver-
gence to a 'best' treatment or until an ' acceptable ' response is reached. Since disease 
processes are dynamic and often chronic, the physician may continue to periodically mon-
itor subjects after the initial optimized dose level is reached, and may restart the titration 
process if changes in the patient's status are observed. 
After a group of subjects has passed through the titration process, the initial and 
final dose locations and corresponding initial and final responses are used to determine 
whether there has been an improvement in response and whether a therapeutic synergism 
exists among the drugs comprising the combination. 
3.3 Inference about the Patient Population 
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The set of final treatment dose combinations observed from then subjects enrolled in the 
study can be considered a sample from a multivariate distribution. We would like both to 
test for an improvement in response after all subjects have passed through the titration 
process and to test the efficacy of the combination or individual components of the combi-
nation. The first goal can be accomplished by identifying it as a one-sample location 
problem on paired responses which can easily be addressed using existing tests, which are 
described in section 3.3.1. The second goal can be accomplished by construction of a p-
dimensional confidence ellipsoid about the central location of the 'cloud' of final dose 
combinations in the p-dimensional dose space. Both a parametric approach and nonpara-
metric approach are described in section 3.3.2. Based on the estimated confidence ellip-
soid, we can evaluate whether a therapeutic synergism (Mantel, 1974) exists between all 
treatments comprising the combination, and we can also estimate a region of improved 
therapy (Carter, 1982). 
3.3.1 The One-Sample Location Problem 
To test for an improvement in response, it is possible to apply the Wilcoxon Signed Rank 
Test (Wilcoxon, 1945) or Fisher Sign Test (Fisher, 1925). We define diff; = Y(k)i - Y(O)i , i = 
1, ... , n, where Y(k)i is the response of the ith subject after undergoing k steps of the titra-
tion process and Y(O)i is the response of the ith subject at baseline. For the signed rank sta-
tistic, we assume the diffj are independent and each comes from a common distribution 
symmetric about 8. We wish to test the hypothesis: 
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where without loss of generality, an increase in response indicates improvement. Forming 
the absolute differences jdiff11, ... jdiff0 I and letting R; denote the rank of the absolute dif-
ferences in the joint ranking from least to greatest of jdiff11,. . .,jdiff0 j, we define 
= {1 if (diffi > O)} . = 
lJ!i 0 if (diffi < 0) ' 1 l,. . ., n 
and 
n 
T+ = I RilJ!i . 
i = I 
A large sample approximation is: 
• T 
Thus, we reject Ho if T • ;::: Za. 
T+- [n(n;l)J 
-;::::::=====-N(O, 1). 
[n(n+ 1)(2n2; l)J 
For the Sign Test, we assume the dif~ are independent and each comes from a dis-
tribution with median 8. We wish to test the hypothesis: H 0 : (8 ~ 0) vs. H 1: (8 > 0). 
We define 
n 
B LlJ!i, 
i = I 
where lJ!i is defined as above, so that Bis the number of positive dif~'s. We reject H0 if 
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B::O:Bin(a,n,~ , 
where Bin( a, n, 112) satisfies 
P0[B~Bin(a,n,DJ a. 
Rejection of the hypothesis of 'no improvement' indicates that the titration process has 
been successful in finding a dose combination which improves the patient's response from 
a baseline response. The responses used in these tests are from the desirability functions 
discussed in section 3 .2.1. Therefore an improved response indicates not only an 
improvement in the primary endpoint of interest but improvement in the overall health sta-
tus of the patient, as defined by the physician through the desirability function. Determi-
nation of sample size and power requirements for the Wilcoxon signed-rank and Fisher 
sign tests are detailed in Lehmann (1975). 
3.3.2 Construction of the Confidence Ellipsoid About a Multivariate Location 
We would like to estimate a region of improved therapy based on the estimated confidence 
ellipsoid about the location of the multivariate distribution of each individual's final treat-
ment combination. If the combination treatment includes p elements, the multivariate 
sampling model involves n independent, identically distributed p-component random vec-
tors x1, ... , xn, each with the p-variate distribution function F(t 1 - 8 1, .. . , tp - 8p), where F 
is absolutely continuous with continuous marginal distribution functions 
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tains the marginal medians, and if each Fj is symmetric, 8 is also the vector of marginal 
means. 
A parametric inferential approach would be to assume a form for F and to con-
struct the confidence ellipsoid for 8. One obvious choice of distribution is the multivariate 
normal. Let x1,x2, ••• ,x0 be a p-variate sample which is i.i.d. 
Np(8 = [81 82 ..• SP]'' L) . The maximum likelihood estimate for 8 is 
n 
1 
-I xi, 
n 
i = I 
and an unbiased estimate (Morrison, 1976) for Lis 
where A 
n 
S = - 1-A 
n - 1 ' 
I (xi - x)(xi- x)' . Since fn(x - 8) - NP(O, L), replacing L with its con-
i = I 
sistent and unbiased estimate and recalling the relationship between Hotelling 's T2 and the 
F distribution, an exact 100( 1-a )% confidence ellipsoid for 8 is 
{8 . (- 8)'S- 1(- 8) dn - l)pp } 
. n x - X - - n _ P 1 - a ; p,n-p · 
For small or medium-sized samples, a more robust approach, which does not 
require distributional assumptions, would be to construct a confidence ellipsoid about the 
multivariate median. An efficient estimator of8 associated with Wilcoxon's Signed Rank 
statistic is the Hodges-Lehmann estimator based on ranks (Hodges and Lehmann, 1963). 
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Let x1,x2,. •• ,xn be a p-variate sample which is i.i.d. F such that the p-vector of marginal 
medians for Fis e = [81 82 ••. SP]' and Fis diagonally symmetric about 8. We can esti-
A 
mate 8 using signed rank statistics (Hettmansperger, 1984). Let Si be the p-vector of 
the sample medians of Walsh averages (Tukey, 1949) with components 
- • IJ I I < . < ., < . -, {(x + x.,.) } ej - median 2 , l _1_1 _n , J - 1, ... ,p. 
If W(l)j :o; W(Z)j :o; ... :o; W(N)j, are the ordered Walsh averages, where N = n(n + 1) 12 , 
the 100(1-a)% confidence interval for 8j is (W(a; + I)j' W(N _ a;)i] , where aj can be 
approximated by 
_ n(n + 1) n(n + 1)(2n + 1) 
aj - 4 - 0.5 - z a 24 
1- 2 
A 
Finding Si is equivalent to finding Si such that the signed rank statistic 
n RS 
°"' ::..=.!l...::.lsign(x - 8) L,. n + 1 IJ J 
i = I 
is approximately equal to zero, where Rijej is the rank of /xij - Si/ among 
1 w = Diag(Yw, 1, • •• , Yw, p) such that 
Yw, j = 2 [ £f(x)dx,j 
-00 
1, ... , p ' 
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and v w is a pxp matrix such that 
and vw,jj = 113 (Hettmansperger, 1998). A consistent estimate of Yw,j> j = 1, ,, . , p is 
found from the asymptotic length ofa confidence interval for ej based on the Walsh aver-
ages(Lehmann, 1975) 
' 
Yw, j 
When the variability is such that a large proportion of subjects arrives at the same, 
or similar, final dose locations, an inordinate number of ties results due to the effect of 
rounding to whole units. As a consequence, w(aj + J)j and w(N - aj)j become identical, 
and the confidence interval for 8j , [W (ai + 1 )j' W (N _ ai)j] , goes to zero. To correct for 
this, we use the smallest viable interval of 2s=0.5 as the lower limit for W(N _ ai)j -
Yw, j 
A consistent estimate of vw, jj'' j , j' 1, .. . , p (Hettmansperger, 1998), is 
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Replacing vw and r w with consistent estimates, an approximate 100(1-a)o/o confidence 
ellipsoid for e is 
After the confidence ellipsoid is established, the ellipsoids can be evaluated using 
the approach described by Carter, et al. (1982). The confidence ellipsoid is evaluated 
along a grid of points on each single axis. As an illustration, in the 2-dimensional case, it 
is determined whether the ellipsoid a) contains the origin, implying the combination is not 
different from no treatment at all; b) contains both axes but not the origin, implying that 
treatment with the combination is better than having no treatment, but that the same 
response could be obtained by using either drug by itself; c) contains only one axis, imply-
ing that treatment with the combination is no better than treatment with the single drug, or 
d) does not contain either axis, implying the presence of a therapeutic synergism, that the 
combination of drugs produces a greater response than either drug alone (Figure 3.2). 
3.4 Simulation Study 
3.4.1 The Response Surface 
A simulation study was performed to examine the effectiveness of the multi-drug titration 
algorithm in combination dosing and the effects of the number of steps, the shape of the 
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desirability function, and the initial step size. The estimated dose response surface was 
obtained from a published multicenter, factorial design clinical trial studying the efficacy 
of the combination therapy of the diuretic hydrochlorothiazide (HCTZ) and a slow-release 
formulation of diltiazem hydrochloride (DLTZ), a calcium channel blocker, in the treat-
ment of mild to moderate hypertension (Burris, et.al., 1990). 
The trial was conducted over a period of six weeks, following a 4- to 6-week pla-
cebo 'run-in' period. A 4 by 5 factorial grid of treatment do1ieS was used, with 4 twice-a-
day doses ofhydrochlorothiazide ranging from 0 to 25 mg, and 5 twice-a-day doses of dil-
tiazem hydrochloride ranging from 0 to 180 mg. Mild-to-moderate essential hypertension 
was defined as supine diastolic blood pressure in the range of95 to 110 mmHg. The goal 
of treatment was to achieve a supine diastolic blood pressure ofless than 90 mmHg, with 
no limiting adverse experience. 261 patients completed the six-week treatment protocol, 
with 13 to 17 patients randomized to each treatment group. 
Using Proc RSREG in SAS, Version 6.12 (SAS Institute, Cary, NC), data from the 
plots published in the study were used to generate the response surfaces for the three main 
variables of interest: diastolic blood pressure (DBP), 4.16+ l .60xHcTZ+0.39xDLTZ-
0.12x2HcTZ+ 0.020x2DLTZ-0.033xHcTZ*xnLTz; serum cholesterol (CHO), 
0.12+0.092xHcTZ+0.033xnLTz-0.0073x2HcTZ- 0.0032x2DL TZ-0.0013xHcTZ*xnLTz ; and 
serum glucose (GLU), -0.12+0.076xHcTZ-O.Ol lxDL TZ-0.0001 lx2HcTZ+ 0.0030x2DLTZ-
0.001 lxHcTZ*xnLTZ· The dose units were converted from milligrams to whole pill 
counts. One pill was equivalent to 3.125mg ofHCTZ or 15mg ofDLTZ. 
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A desirability function was defined for each of these three variables, d 1-d3 (Figure 
3.3) and combined into an overall desirability function, D=(d1 *d2*d3) 113. The Nelder-
Mead simplex procedure was then used to carry out the titration using the composite desir-
ability. The Nelder-Mead algorithm is run on a continuous scale to maintain the flexibility 
allowed by simplexes of differing shapes. Therefore at each step, to determine the next 
dose combination, the doses output by the algorithm are rounded to the nearest whole dose 
unit. As discussed previously, it is also possible to round down to the nearest integer 
value. 
3.4.2 Simulation Example 
For each subject, the starting dose for the initial simplex was chosen to be the same as the 
smallest combination dose used in the original study: 6.25mg (2 pills) ofHCTZ and 60mg 
(4 pills) ofDLTZ. The initial step size was chosen to be the initial dose combination 
increased by four pill counts. 
In order to simulate subject responses more realistically, a mixed effects model 
with a first order autoregressive covariance structure was used. Let Yij=xi/P+i::ij> where Yij 
represents the jth response from the ith subject, xi;=[l xi1 xiz xi12 xi22 xi1xi2] represents the 
6x 1 vector of doses and dose functions for the ith subject at the jth time point, p represents 
the 6x 1 vector of parameters taken from the study, and Eij represents the random error. 
The covariance between two observations w time intervals apart on the same subject is 
crE2pw, where pis the correlation between adjacent observations within the same subject, 
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and w is the number of time intervals between the observations. For this study, the root 
MSE for DBP, aDBP, was 6.2mmHg (pers. comm.), and 0.35mmol/L was used for both 
CHO, crcHo , and GLU, crGLU· 
The simulated response at each vertex of the simplex was obtained in triplicate and 
the responses were averaged. The desirability for each averaged response was compared, 
and the location of the next dose combination to be given was determined by the Nelder-
Mead algorithm, rounding to the nearest whole pill. The titration continued through the 
specified fixed number of steps (either 16 or 32). At the last step, the final simplex was 
evaluated and the dose combination associated with the most desirable response was taken 
as the final treatment combination. Figure 3.4 demonstrates the final dose locations for a 
simulated group of 175 subjects who have completed the titration process. The mean final 
dose combination was 4.6 pills HCTZ and 16.2 pills DLTZ with a simulated mean 
decrease in DBP of 17.7mmHg. Figure 3.5 shows the asymptotic confidence ellipsoid 
about the central location estimate for the Wilcoxon Signed Rank statistic. A correlation 
between successive blood pressure observations of p=O. 7 was used and the process con tin-
ued for 16 steps. 
3.4.3 Simulation Results 
Five groups of 100 simulations were run using sample sizes ofN=l 75 with 16 and 32 
steps. The simulations were run first using the desirability function for DBP alone, d1 
(Fig. 3a), and then repeated using the composite desirability function, D=(d1*d2*d3) 1/ 3, 
which took into account serum cholesterol and serum glucose measurements in addition to 
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the DBP. Additionally, to examine the effect of the correlation between successive obser-
vations, p, the correlation was varied from 0.1 to 0.8. In the simulations with the compos-
ite desirability function, the correlation between successive DBP measurements was 
varied from 0.1 to 0.8, while the correlations for both CHO and GLU were fixed at 0.7. 
Using the desirability function for DBP, d1, we see in Table 3.2 that the proportion 
of subjects showing improvement over the baseline was 1 (i.e. 100%) for all cases, using 
either the Fisher Sign test or the Wilcoxon Signed Rank test. All subjects also showed 
improvement when the final response was compared to the simulated response to single 
drug treatment with 25mg ofHCTZ, the highest dose used in the study. A similar result 
was seen in comparing the response to treatment with a 180mg dose ofDLTZ. The mean 
decrease in DBP, shown in the far right column, did not appear to change as the number of 
steps was increased from 16 to 32. However, the size of the reduction in DBP did appear 
to increase as the correlation increased. Table 3.3 shows the percentage of confidence 
ellipsoids which included the origin, included the hydrochlorothiazide axis only, included 
the diltiazem axis only, or included both axes, also using the desirability for DBP alone. 
The final central dose locations for hydrochlorothiazide and diltiazem are also given in the 
far right columns, using both the mean and the Wilcoxon Signed Rank statistics as mea-
sures of central location. Using Mardia's test (1974), in many instances the multivariate 
distribution of the final dose locations for each simulation showed some departure from 
normality, suggesting the nonparametric approach to be most appropriate. As the correla-
tion was increased from 0.1to0.8, the simplex appeared to move further up the DLTZ 
axis, resulting in a higher final dose ofDLTZ and a tighter confidence ellipsoid. Increas-
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ing the number of steps from 16 to 32 did not appear to have much effect, suggesting that 
the simplex had already arrived at a final dose after 16 steps. 
From our simulations, it appears that the evolutionary simplex approach is effec-
tive in arriving at dose combinations producing improved responses in patients being 
treated with multiple drug regimens, although inferences on the location do not appear to 
be as sharp as inferences on the response. In comparing the simulation results with the 
original response data, the final dose locations were found to correspond well with the 
area of higher response seen in the Burris, et.al. study. 
The simulations were then repeated using the composite desirability function, D, 
which combined the main outcome of interest, DBP, with two other endpoints which the 
study authors reported, serum glucose and serum cholesterol. The correlation for succes-
sive DBP measurements within a patient was increased from 0.1 to 0.8, while the correla-
tion for both CHO and GLU were fixed at 0.7. In Tables 3.4 and 3.5, we see that the 
simplex does not move as far along the DLTZ axis or HCTZ axis when these other end-
points are taken into consideration. However, from Table 3.4, we see that even at these 
doses, there is still a significant improvement in the response for all subjects in all cases. 
We were also interested in determining how sensitive the titration method was to 
variability in the chosen desirability function. To determine whether small modifications 
in the desirability function had any effect on the resulting dose locations and responses, 
we ran simulations using three modified desirability functions in addition to d1, the desir-
ability function for DBP, with 16 steps, a correlation of0.7, and a sample size of 175. 
Tables 3.6 and 3.7 show that sharpening the peak desirability as with da, increasing the 
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width of the desirability function as with db, or decreasing the width and sharpening the 
peak simultaneously as with d0 did not result in any appreciable change in the outcome 
with respect to either response or dose location. There was little or no change in the 
decrease in DBP or final dose combinations, indicating that the process is robust, or rela-
tively insensitive, to small changes in the definition of the desirability function. So while 
desirability functions should be defined carefully, there is some room for variation when 
deciding on the parameters. 
To examine the effect of changing the initial step size, the step size was changed 
from an increase of 6 pills in the HCTZ axis and 8 pills in the DLTZ axis, to an increase of 
only 5 pills/7 pills, or 4 pills/6 pills over the initial dose combination. After 16 steps, 
using the desirability function for DBP, a correlation of0.7, and a sample size of 175, 
there was a slightly smaller decrease in the DBP response. In addition, the final dose com-
binations also decreased as the initial step size became smaller. This would suggest that 
either the simplex has not had enough time to reach the same improved dose as with the 
larger step size, or perhaps the simplex has reached a plateau and the variability is too 
large for it to moye further along the dose response surface. However, increasing the 
number of steps from 16 steps to 32 steps did not noticeably change the results, suggesting 
that the latter situation might be the cause of the differences in the outcome measures. 
This underscores the need to be prudent in choosing the parameters for the Nelder-Mead 
algorithm. 
3.5 Discussion 
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In this paper, we have demonstrated the application of a method for titrating and evaluat-
ing multiple drug combinations within individual patients. This approach is well suited to 
the treatment of chronic diseases with long courses, where the condition of the patient is 
constantly evolving, and it lends itself especially well to conditions with a readily mea-
sured response, where there are regular treatment intervals, and where dose escalation 
within a patient is reasonable. After the patient completes an initial titration, the patient 
can continue to be monitored with periodic measurements of the response or marker of 
interest, and the simplex can be restarted ifthe treatment appears to need later adjustment. 
Some care must be used when determining parameters to use for the initial step size, for 
the reflection, expansion, and contraction coefficients, and for the stopping criteria. This 
requires a close collaboration between the statistician and physician investigator. The 
choice of these parameters will be affected by the variability in the response and the thera-
peutic index of the drugs involved. However, there is flexibility built into the procedure 
which allows one to start with a more cautious approach and to modify the conservative-
ness as the titration progresses. 
This method of patient titration can be used in a modified clinical trials setting to 
evaluate the efficacy of a therapy composed of a combination of therapeutic agents. The 
first step would be for the physician researcher and statistician to define the desirability 
function for each response of interest, develop a composite desirability, and specify the 
parameters for the direct-search algorithm. A regular treatment or visit schedule should be 
set up so the physician can regularly monitor the patient response. The patient will be 
treated with each of the dose combinations comprising the initial simplex, with a change 
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in the treatment dose occurring at pre-specified intervals. After the initial simplex is 
established, the physician can run the direct search procedure himself, using specially 
designed software to determine the next combination of doses to administer; or, he can 
report the results to a central statistician or agency who can then advise the physician on 
the next dose combination to prescribe. This titration is then continued for the duration of 
the study. Inference on the sample of patients can then be made using the methods 
described in this paper. 
This method has several advantages over the approach often used in clinical trials. 
One key advantage is that each patient has the potential to benefit from the treatment 
being administered. In contrast, in the typical clinical trials setting, a large percentage of 
patients, specifically, those randomized to the placebo group, often receive no benefit 
from the trial, leading to problems with patient recruitment and compliance with the study 
protocol. Another important advantage is the flexibility inherent in this approach. While 
this method is easily automated, it allows the investigator to incorporate his own experi-
ence and knowledge about the response and to include multiple outcomes of interest as 
well as multiple constraints, mirroring the way physicians approach dose titration in prac-
tice. 
This approach also has advantages over the response surface methods sometimes 
used to evaluate multiple drug combinations. Response surface methods usually require 
the inclusion of many dose levels and dose combinations. This results in studies that are 
expensive and where there is no guarantee that any of the study subjects receives the opti-
mum dose. Furthermore, the response surface approach requires an assumption that the 
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dose-response relationship is well approximated by the equation specified. 
The method discussed in this paper does not require specifying the form of the 
dose-response relationship and automatically takes into account interactions between ther-
apeutic components. It allows investigators to easily evaluate for the presence or absence 
of therapeutic synergism and to determine whether subjects have experienced an improve-
ment in outcome. 
In our simulation studies, we simulated how this method would work in titrating 
two blood pressure medications within patients with mild to moderate hypertension, using 
the response surface data provided in the study by Burris, et.al. Our studies demonstrated 
that with proper choice of the initial simplex and step size, all simulated subjects experi-
enced an improvement in response over the baseline, with a significant decrease in the 
diastolic blood pressure. Minor changes to the desirability function did not appear to 
modify the results significantly, demonstrating some resilience in the specification of the 
desirability function. Modifying, or more specifically, decreasing, the size of the initial 
step in the Nelder-Mead algorithm, did appear to have some effect on the final dose loca-
tions, emphasizing that the careful choice of the initial step size, reflection, expansion, and 
contraction coefficients, is critical in the application of this methodology. Use ofMardia's 
multivariate test for normality showed that the final dose locations did not generally fol-
low a multivariate normal distribution, suggesting that the use of the nonparametric 
approach when constructing confidence ellipsoids would be more appropriate. The confi-
dence ellipsoid then provides a way to evaluate therapeutic synergism and to make infer-
ences about the treatment efficacy of individual therapeutic components. 
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There are several limitations to this approach that should be addressed. One possi-
hie criticism is that there is no control group in the titration process to provide internal val-
idation. As a result, it could be argued that the improvement in response displayed by the 
group ofn patients may be due simply to physician attention or the possibility that the dis-
ease has gone into remission. This should be considered when interpreting the results of 
the statistical tests discussed in section 3.3.1. One possible solution is for researchers to 
provide some form of external validity. For example, the investigator may find published 
reports on a similar patient population showing a lack of patient improvement in untreated 
patients or patients undergoing monotherapy. 
This method is also likely to be sensitive to the number of drugs comprising the 
combination under evaluation. As the number of therapies in a combination increases 
above a certain level, this method may become cumbersome due to time constraints and 
compliance problems in establishing the initial simplex. The subject would be required to 
rotate through numerous sets of different dose combinations to establish the initial simplex 
before information useful for treatment could be collected and applied. On the other hand, 
the alternative, using response surface methodology, would also be impractical because of 
the extremely large number of subjects which would be required. In addition, it is unlikely 
that the number of drugs in a combination would reach the level where this might become 
problematic. 
Another limitation is that this method may be less efficient in specific cases, e.g., 
when the variability in the response value is large relative to the effect, resulting in too 
much noise in the system, or when the time required to observe a response is overly long, 
making the establishment of the initial simplex impractical. Additionally, the simplex 
movement may move too slowly to be of benefit in treating the patient. 
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In conclusion, we have described an evolutionary operation approach to evaluating 
multiple drug therapies while simultaneously titrating therapies within individual patients, 
where every patient has the potential to benefit from the combination being studied. This 
flexible approach is useful not only in titrating multiple agents, but also can similarly be 
applied to the titration of single agents with multiple endpoints. The utilization of desir-
ability functions allows us to emulate how physicians approach dose titration in the single 
drug case, allowing the consideration of multiple endpoints and constraints. Practicing 
physicians may find this approach useful for improving the way both single therapies and 
combination therapies are prescribed for individual patients. Clinical researchers may 
find this methodology useful for evaluating whether therapeutic synergism exists within 
specific drug combinations and for evaluating individual therapeutic components. 
The current procedure is not far from the one described by Box in 1958. He envi-
sioned using evolutionary methods which "might in fact be used to get maximum informa-
tion from the normal treatment of patients by practicing practitioners. It would be 
necessary for a central agency to obtain agreement that doctors, in using a particular ther-
apy in normal practice (as contrasted with special research studies), would vary the ther-
apy slightly in accordance with a prescribed plan. With a suitable statistical plan, 
differences arising from small deliberate changes in the therapy can be detected when the 
information is collected. In this way a steady evolution in medical practice might be set in 
motion to augment more specialized research studies." This 'evolution in medical prac-
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tice' was anticipated by Box over 40 years ago, where practicing physicians would apply 
evolutionary principles in the treatment of their patients, with a parallel evolvement in the 
conduct of clinical research studies. Certainly there is technology currently available 
which would allow the physician to enter the patient data directly into a handheld com-
puter or personal digital assistant, to calculate the desirabilities, and to run the evolution-
ary direct search procedure at the bedside to obtain an immediate prescription. With drug 
consumption continuing to rise, and along with that the dramatic increase in the potential 
for drug interactions, new approaches to prescribing and treatment are needed. Our meth-
odology may be useful for both treating the individual patient and for characterizing new 
drug combinations. 
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3.6 Figures 
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Figure 3.1: Examples of desirability functions: (a) target desirability function for fasting 
plasma glucose; (b) minimizing desirability function for increase in body weight. Cases 
are from Table 3 .1. 
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Figure 3.2: Evaluating confidence ellipsoids 
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Figure 3.3: Desirability functions: (a) decrease in diastolic blood pressure; 
(b) increase in cholesterol; ( c) increase in glucose. 
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Figure 3.5: Asymptotic confidence ellipsoid based on the Wilcoxon signed rank statistic 
for a group of 175 subjects using the desirability function in Figure 3.3a. 
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3.7 Tables 
Table 3.1: Desirability example for differing fasting plasma glucose and weight gain 
levels . D=(dl *d2) 112 . 
Case 1 
Case 2 
Case 3 
FPG (mg/dL) d1 Weight Gain (lbs) dz D 
140 
155 
160 
0.95 
0.19 
0.05 
10 
30 
0 
1.0 0.98 
0.5 0.31 
1.0 0.22 
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Table 3.2: Proportion of improved responses using the Fisher sign test or Wilcoxon 
signed-rank test. Simulations were done using the desirability function for diastolic blood 
pressure alone (d1) . The mean decrease in DBP is shown in the far right column. 
HCTZ DLTZ 
Decrease 
N Steps p Baseline Alone Alone inDBP (mmHg) 
175 16 0.1 Fisher(SE) I 6.4 
Wilc(SE) 
0.3 Fisher(SE) 16.8 
Wilc(SE) 
0.5 Fisher(SE) 16.9 
Wile( SE) 
0.7 Fisher(SE) 17.7 
Wilc(SE) 
0.8 Fisher(SE) 18.6 
Wilc(SE) 
32 0.1 Fisher(SE) 16.3 
Wilc(SE) 
0.3 Fisher(SE) 16.9 
Wilc(SE) 
0.5 Fisher(SE) 17.1 
Wilc(SE) 
0.7 Fisher(SE) 18.2 
Wilc(SE) 
0.8 Fisher(SE) 18.6 
Wilc(SE) 
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Table 3.3: Evaluation of the confidence ellipsoids using a parametric and nonparametric 
approach. Simulations were done using the desirability function for diastolic blood 
pressure alone (d 1). The columns show the percentage of confidence ellipsoids (SE) 
containing the origin, containing the DLTZ axis only, containing the HCTZ axis only, or 
containing both axes. The rightmost columns show the final dose locations for HCTZ and 
DLTZ using either the mean or Wilcoxon signed-rank statistic as the measure of central 
location. 
N Steps Origin HCTZ DLTZ Both Axes Final Dose Final Dose p Axis Only Axis Only HCTZ DLTZ 
175 16 0.1 Mean(SE) 0 0 97.2(1.30) 2.8(1.30) 4.5(0.03) 14.0(0.02) 
Wile( SE) 1.6(1.52) 13.4(2.92) 39.0(2.92) 23.2(4.97) 4.4(0.03) 14.2(0.03) 
0.3 Mean(SE) 0 0 99.6(0.89) 0.4(0.89) 4.5(0.02) 14.5(0.01) 
Wilc(SE) 0.8(0.45) 9.6(2.70) 43.4(4.22) 16.2(3.27) 4.4(0.03) 14.7(0.01) 
0.5 Mean(SE) 0 0 100 0 4.5(0.02) 15.2(0.02) 
Wilc(SE) 0 4.8(1.92) 51.2(5.12) 8.2(2.17) 4.4(0.02) 15.5(0.03) 
0.7 Mean(SE) 0 0 100 0 4.6(0.02) 16.2(0.02) 
Wilc(SE) 0 0.4(0.89) 64.6(5.50) 0.4(0.89) 4.5(0.02) 16.6(0.03) 
0.8 Mean(SE) 0 0 100 0 4.6(0.02) 17.1(0.02) 
Wilc(SE) 0 0 68.0(3.94) 0 4.5(0.03) 17.3(0.03) 
32 0.1 Mean(SE) 0 0 99.4(0.55) 0.6(0.55) 4.4(0.01) 14.2(0.05) 
Wilc(SE) 0.6(0.55) I 0.8(4.87) 49.4(4.10) 21.8(4.44) 4.2(0.02) 14.4(0.05) 
0.3 Mean( SE) 0 0 100 0 4.4(0.01) 14.7(0.06) 
Wilc(SE) 0.2(0.45) 8.2(0.84) 54.0(3.87) 17.6(2.30) 4.3(0.02) 15.0(0.07) 
0.5 Mean(SE) 0 0 100 0 4.4(0.02) 15.3(0.03) 
Wile (SE) 0 2.6(1.14) 61.4(8.88) 5.6(1.95) 4.3(0.02) 15.7(0.02) 
0.7 Mean (SE) 0 0 100 0 4.5(0.02) 16.4(0.01) 
Wile (SE) 0 0 71.0(3.87) 0 4.4(0.02) 16.7(0.02) 
0.8 Mean (SE) 0 0 100 0 4.5(0.004) 17.1(0.04) 
Wile (SE) 0 0 75.4(2.30) 0 4.4(0.01) 17.4(0.05) 
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Table 3.4: Proportion of improved responses using the Fisher sign test or Wilcoxon 
signed-rank test. Simulations were done using the composite desirability function (D). 
The correlation between successive DBP measurements was varied from 0.1 to 0.8, while 
the correlations for both CHO and GLU were fixed at 0.7. The rightmost columns show 
the mean decrease in diastolic blood pressure, the mean change in cholesterol and the 
mean change in serum glucose. 
HCTZ OLTZ Decrease Change Change in N Steps p Baseline Alone Alone inDBP in Chol Glu (mmHg) (mmol/L) (mmol/L) 
175 16 0. 1 Fisher (SE) I 1.9 0.24 0.29 
Wile (SE) 
0.3 Fisher (SE) 11.9 0.25 0.29 
Wile (SE) 
0.5 Fisher (SE) I 1.9 0.25 0.3 1 
Wile (SE) 
0.7 Fisher (SE) 12.0 0.24 0.29 
Wile (SE) 
0.8 Fisher (SE) 12.1 0.24 0.27 
Wilc (SE) 
32 0.1 Fisher (SE) 11.3 0.25 0.27 
Wile(SE) 
0.3 Fisher (SE) 11.3 0.27 0.26 
Wile (SE) 
0.5 Fisher (SE) 11.6 0.25 0.3 1 
Wile (SE) 
0.7 Fisher (SE) 11.9 0.24 0.27 
Wile (SE) 
0.8 Fisher (SE) 11.8 0.23 0.27 
Wilc (SE) 
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Table 3.5: Evaluation of the confidence ellipsoids using a parametric and nonparametric 
approach. Simulations were done using the composite desirability function (D). The 
correlation between successive DBP measurements was varied from 0.1 to 0.8, while the 
correlations for both CHO and GLU were fixed at 0.7. The columns show the percentage 
of confidence ellipsoids (SE) containing the origin, containing the DLTZ axis only, 
containing the HCTZ axis only, or containing both axes. The rightmost columns show the 
final dose locations for HCTZ and DLTZ using either the mean or Wilcoxon signed-rank 
statistic as the measure of central location. 
HCTZ DLTZ Axis Final Final N Steps p Origin Axis Only Only Both Axes Dose Dose 
HCTZ DLTZ 
175 16 0.1 Mean (SE) 0 0 34.0(5.70) 66.0(5.70) 3.1(0.02) 9.2(0.02) 
Wile (SE) 9.0(1.41) 0 61.4(2.07) 38.6(2.07) 3.0(0.02) 9.2(0.02) 
0.3 Mean (SE) 0 0 35.6(3.05) 64.4(3.05) 3. 1(0.02) 9.2(0.02) 
Wilc(SE) 8.8(4.92) 0 60.8(4.32) 39.2(4.32) 3.0(0.02) 9.3(0.03) 
0.5 Mean (SE) 0 0 38.2(4.44) 61.8(4.44) 3. 1(0.02) 9.3(0.02) 
Wile (SE) 9.8(2.28) 0 61.4(2.70) 38.6(2.70) 3.0(0.02) 9.4(0.02) 
0.7 Mean (SE) 0 0 44.0(5.24) 56.0(5.24) 3. 1(0.02) 9.4(0.02) 
Wile (SE) 8.8(3.27) 0 61.4(5.77) 38.6(5.77) 3.0(0.0 1) 9.5(0.02) 
0.8 Mean (SE) 0 0 51.4(3.58) 48.6(3.58) 3. 1(0.02) 9.5(0.02) 
Wile (SE) 9.2(2. l 7) 0 59.8(4.21 ) 40.2(4.21) 3.0(0.02) 9.6(0.03) 
32 0.1 Mean (SE) 0 0 36.4(3. 71) 63.6(3.71) 3.0(0.02) 9.2(0.03) 
Wilc(SE) 9.2(1.64) 0 59.2(5.26) 40.8(5.26) 2.8(0.03) 9.3(0.03) 
0.3 Mean (SE) 0 0 38.6(3.78) 6 1.4(3.7£) 3.0(0.02) 9.2(0.04) 
Wile (SE) 6.4(1.67) 0 56.4(3. 13) 43.6(3. 13) 2.8(0.02) 9.3(0.04) 
0.5 Mean (SE) 0 0 40.8(3.56) 59.2(3.96) 3.0(0.0 l) 9.3(0.05) 
Wilc(SE) 5.2(2.05) 0 55.0(3.39) 45.0(3.39) 2.8(0.01) 9.4(0.05) 
0.7 Mean (SE) 0 0 48.6(4.1 6) 5 1.4(4.16) 2.9(0.01) 9.4(0.03) 
Wile (SE) 7.0(2.55) 0 59.4(2.07) 40.6(2.07) 2.8(0.02) 9.5(0.03) 
0.8 Mean (SE) 0 0 54.2(1.92) 45.8(1.92) 2.9(0.0 l) 9.5(0.04) 
Wile (SE) 6.8(2.17) 0 53.0(3.54) 47.0(3.54) 2.8(0.02) 9.6(0.04) 
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Table 3.6: A comparison of desirability functions. The table shows the proportion of 
improved responses using the Fisher sign test or the Wilcoxon signed-rank test. The 
parameters for the modified desirability functions are shown, with the mean decrease in 
diastolic blood pressure given in the rightmost column. 
N=l75 
HCTZ DLTZ Decrease Dsbl Steps= l6 cv,.-,v,'·) cv,.- ·,v:··l Baseline Alone Alone inDBP p=0.7 (mmHg) 
d1 Fisher (SE) (0,10) (30,40) 17.7 
Wilc(SE) 
da Fisher (SE) (0,20) (20,40) 17.5 
Wile (SE) 
db Fisher (SE) (-5, 10) (30,45) 17.5 
Wi lc(SE) 
de Fisher (SE) (10,20) (20,30) 17.5 
Wile (SE) 
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Table 3.7: A comparison of desirability functions. The columns show the percentage of 
confidence ellipsoids (SE) containing the origin, containing the DLTZ axis only, 
containing the HCTZ axis only, or containing both axes. The parameters for the modified 
desirability functions are shown, with the rightmost columns giving the final dose 
locations for HCTZ and DLTZ using either the mean or Wilcoxon signed-rank statistic as 
the measure of central location. 
N= l 75 
Dsbl Steps= 16 (Yi'',Y(") (Y;•",Y;"') Origin 
p=0.7 
d1 Mean (SE) (0, 10) (30,40) 0 
Wilc(SE) 0 
da Mean (SE) (0,20) (20,40) 0 
Wilc(SE) 0 
db Mean (SE) (-5,10) (30,45) 0 
Wile (SE) 0 
de Mean (SE) (I 0,20) (20,30) 0 
Wile (SE) 0 
HCTZ 
Axis 
Only 
0 
DLTZ 
Axis Only 
100 
Both 
Axes 
0 
Final 
Dose 
HCTZ 
4.6(0.02) 
Final Dose 
OLTZ 
16.2(0.02) 
0.4(0.89) 64.6(5.50) 0.4(0.89) 4.5(0.02) 16.6(0.03) 
0 100 0 4.6(0.01) 16.3(0.03) 
0.2(0.45) 64.0(3.81) 0.2(0.45) 4.5(0.02) 16.6(0.04) 
0 100 0 4.6(0.02) 16.3(0.02) 
0.4(0.55) 66.8(3.90) 0.4(0.89) 4.4(0.03) I 6.6(0.04) 
0 100 0 4.6(0.01 ) 16.3(0.02) 
0.2(0.45) 63.6(3.44) 0.2(0.45) 4.5(0.02) 16.6(0.04) 
Chapter 4 
Applications of EVOP Titration 
4.1 Discussion of Clinical Applications 
There are many diseases or clinical syndromes to which the evolutionary operation direct-
search titration methodology could be applied. The characteristics of a condition which 
would favor its use include an easily and rapidly measured response, a lengthy time 
course, and a condition where dose escalation within a patient is reasonable. Examples of 
diseases or syndromes which may benefit from this treatment approach are hypertension, 
diabetes, rheumatoid arthritis, asthma, AIDS, and some cancers. 
It is important that the responses being monitored are easily measureable and 
reproducible. In the ideal case, they might consist of laboratory tests or measurements 
that are already performed periodically as part of the regular standard of care so as to min-
imize additional discomfort or inconvenience to the patient. Accuracy and reproducibility 
of measurement are also important to ensure that the simplex is moving purposefully 
according to the clinical endpoint (or signal) rather than moving haphazardly in response 
to a large variability in the measurement (or noise). Some examples of suitable clinical 
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endpoints are blood pressure, fasting plasma glucose, forced expiratory volume, and the 
reported number of side effects a patient is experiencing each week. 
In the situation where a lengthy time to response is required, the use ofEVOP may 
not be appropriate. A sufficient time interval between measurements must be allowed to 
preclude any carryover effects from the previous treatment. In this case, the time required 
to set up the initial simplex may become impractical, and the subsequent simplex move-
ment may be too slow to be of benefit in treating the patient. EVOP titration may also be 
problematic when the number of therapies in a combination is extremely large. Establish-
ing the initial simplex may become cumbersome due to time constraints, and problems 
with patient compliance are more likely. EVOP would also be of limited application when 
the course of a disease is too brief to provide substantial information. 
On the other hand, the application ofEVOP is very well suited to the treatment of 
chronic conditions with long time courses. This allows sufficient time for the establish-
ment of the initial simplex and for titration to a maintenance therapy. Since disease pro-
cesses are dynamic, EVOP can be continued indefinitely to track the patient's progress. 
After an initial maintenance dose is identified, the physician can continue to periodically 
monitor the patient, and the titration process can be restarted when changes to the patient's 
status are observed. 
The following section is an example of a study protocol applying the evolutionary 
operation direct-seach methodology to the treatment of type 2 diabetes patients. 
4.2 Study Protocol using EVOP Direct-Search Methodology 
A comparison of multi-drug titration with glyburide and metformin to 
treatment with Glucovance 
4.2.1 Hypothesis 
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Drug titration within individual patients using the two drug combination of glyburide and 
metformin results in a higher proportion of patients achieving target HbA1c when com-
pared to fixed dosing with Glucovance. 
4.2.2 Specific Aims 
Preliminary 
To conduct a twenty week pilot study to determine the proportion of subjects achieving a 
target HbA 1 c < 7% after treatment with a 2-drug titration approach using glyburide and 
metformin in combination, and to adjust, if necessary, the titration parameters to be used 
in the primary study. 
Primary 
To determine whether a 2-drug titration approach using glyburide and metformin in com-
bination is superior to fixed dosing with Glucovance in achieving acceptable serum glu-
cose levels, using a test of proportions to determine whether the proportion of subjects 
achieving a target HbA 1c < 7% using the titration approach is as large as that for Gluco-
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vance after 24 weeks. 
Secondary 
To determine whether a 2-drug titration approach using glyburide and metformin in com-
bination results in a more desirable outcome status after 24 weeks than treatment with 
Glucovance, using a test of mean final desirability scores. 
4.2.3 Background and Significance 
It is estimated that approximately 16 million people in the U.S. have diabetes, only one-
third of which are diagnosed. Type 2 diabetes accounts for 90-95% of all patients diag-
nosed with diabetes. An additional 15 million people have impaired glucose tolerance, 
putting them at a high risk for developing type 2 diabetes. Diabetes is currently the 4th 
leading cause of death by disease in the U.S., the leading cause of blindness in adults 20-
74 years old, and the leading cause of end-stage renal disease. Sixty to seventy percent of 
diabetics have some form of mild to severe neuropathy, and diabetes is associated with a 2 
to 4 fold increase in risk for both heart disease and stroke. The considerable morbidity and 
mortality associated with this disease is estimated to cost $98 billion each year in direct 
medical costs and indirect costs to industry (1). 
Recent reports (2,3) have added to the evidence that tighter glycemic control may 
delay or prevent both macrovascular disease and microvascular and neuropathic complica-
tions. Therefore it is of significant interest, both from the point of view of reducing mor-
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bidity and mortality and of controlling health care costs, to find the most efficient strategy 
for applying our current arsenal of diabetes therapies to achieve the tightest glycemic con-
trol. 
In recent years, several new oral therapeutic agents have been introduced to treat 
diabetes, which has opened up new options for managing this disease. Diabetes treatment 
is typically first approached by recommending changes to both diet and activity levels. If 
treatment with lifestyle changes alone is unsuccessful, the physician has a choice of sev-
eral oral agents that may be added alone or in combination to the treatment plan, including 
sulfonylureas, biguanides (metformin), alpha-glucosidase inhibitors and the thiazo-
lidinediones. 
The current therapeutic approach to treating type 2 diabetes is often first to find an 
effective dose with a single drug and then to incrementally increase levels of the drug to 
maintain the effect as time progresses. Currently, all type 2 diabetes treatments show sec-
ondary failure over time (4,5), with HbA1c levels increasing by 0.2 to 0.3 percent per year 
(4). Therefore, all treatments must be subject to continuous adjustment and periodic 
increases. When the maximum dose of the single drug is reached or the single drug is no 
longer sufficient to maintain acceptable glucose levels, a new compound is often added to 
keep serum glucose measurements within the allowable range while keeping the first com-
pound at its maximum dose. Such an approach, however, does not account for potential 
interactions among the drugs, and it is possible that the patient is not receiving the best 
available treatment. In addition, several studies have examined the use and benefits of 
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combination therapies, including the combination of sulfonylureas with metformin 
(6,7,8), and there is some evidence that these drugs, used in combination, provide better 
glucose control than either drug by itself ( 6, 7). One company, Bristol-Myers Squibb, has 
combined the sulfonylurea, glyburide, with the biguanide, metformin, into a single tablet, 
recently approved and currently sold in the U.S. under the name Glucovance. 
A preliminary study often type 2 diabetes patients will be conducted over a period 
of twenty weeks using an evolutionary operation (EVOP) approach to titrating the 2-drug 
combination of glyburide and metformin within each subject. The preliminary study will 
allow the fine tuning of the parameters used in the titration procedure before beginning the 
primary study. An estimate will also be obtained of the proportion of subjects attaining a 
HbA1c < 7%, which will be used to calculate the required sample size for the primary 
study. 
The purpose of the primary study is to determine whether titration with the 2-drug 
combination of glyburide and metformin in type 2 diabetes reduces HbA 1 c levels more 
effectively than treatment with fixed doses of Glucovance over a period of 24 weeks. 
4.2.4 Review of Therapeutic Agents 
Sulfonylureas (tolbutamide, chlorpropamide, tolazamide acetohexamide, glyburide, glip-
izide, glimepiride) 
The sulfonylureas are a group of agents that increase insulin secretion by stimulating pan-
creatic beta cells (9). They are effective in lowering glycemia in about 50 percent of 
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patients who are unable to control their glycemia with diet and exercise alone (10). The 
effectiveness declines as the failure of the beta cells progresses, resulting in a secondary 
failure rate of3 to 10 percent per year (10). The average decrease in HbA1c is 1 to 2 per-
cent (11). There is a small risk of hypoglycemia with use of the sulfonylureas and a mod-
est associated weight gain. The effects on the lipid profile are minimal, with minor 
decreases in triglyceride levels. Treatment should be initiated at the lowest recommended 
dose and increased every four to seven days until the desired effect or maximum dose is 
reached. 
Glyburide is a second generation sulfonylurea, administered twice a day in doses 
ranging from 1.25mg to 5mg, with a maximum daily dose of 20mg. 
Biguanides (metformin) 
Metformin is the only biguanide currently approved for use in the U.S. by the FDA. It acts 
on the liver to decrease hepatic glucose production and also promotes insulin sensitivity in 
both the liver and peripheral tissues (12). Treatment with metformin has been shown to 
decrease fasting and postprandial glycemia by 60-70mg/dL (13), with an average decrease 
in HbA 1cof1.5 to 2 percent (13). Metformin shows initial effectiveness in approximately 
75 to 80 percent of type 2 diabetes patients (9) and does not cause hypoglycemia. It is 
associated with less weight gain than the sulfonylureas (12) and is often used in combina-
tion with the sulfonylureas or with other agents. It also appears to have favorable effects 
on the lipid profile and is associated with small decreases in total cholesterol, LDL and 
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triglyceride levels (14). There are some gastrointestinal side effects, most notably nausea 
or diarrhea, which can be minimized by taking metformin with meals, and by initiating 
treatment at a low dosage and increasing the dose slowly over a period of several weeks. 
The most serious side effect is lactic acidosis (15), particularly in patients with impaired 
renal function. Therefore, metformin cannot be used when the creatinine clearance is 
greater than 1.4mg/dL in women, and greater than l .5mg/dL in men. Metformin is also 
contraindicated in cardiac failure and pulmonary disease patients or anybody with a dis-
ease condition which interferes with lactate removal. Treatment with metformin is usually 
initiated at a dose of 500 mg, which may be increased in 500 mg increments every one to 
two weeks, with the maximum effect seen at a dose of2000mg per day. 
Glucovance 
Glucovance is a combination of the sulfonylurea, glyburide, and the biguanide, met-
formin. It has been approved for use both as an initial adjunct therapy to diet and exercise 
and a second-line therapy in patients who have not successfully controlled their hypergly-
cemia with diet, exercise, or treatment with a sulfonylurea or metformin alone. Gluco-
vance is available in fixed combination doses of l .25mg glyburide/250mg metformin, 
2.5mg/500mg, and 5mg/500mg, with a maximum daily dose of20mg/2000mg. An 
unpublished study of 806 previously untreated type 2 diabetes patients, summarized on the 
package insert (16), found a mean change from baseline HbA1c of 1.48% at 20 weeks 
treatment with Glucovance l .25mg/250mg compared to a mean change from baseline of 
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1.24% for glyburide, and 1.03% for metformin. Information from another unpublished 
study, also summarized on the Glucovance package insert, involved 639 type 2 diabetes 
patients whose blood sugar was inadequately controlled with sulfonylureas alone. These 
patients were either given glyburide 20mg, metformin 500mg, Glucovance 2.5/500mg, or 
Glucovance 5/500mg. At the end of 16 weeks, the mean HbA 1 c value of patients given 
either dose of Glucovance was reported as 1. 7% lower than those treated with glyburide 
alone, and 1.9% lower than those treated with metformin alone (16, 17). 
Current ADA Guidelines for Glycemic Control (18) 
Preprandial Glucose 80-120 mg/dL 
Bedtime Glucose 100-140 mg/dL 
HbAlc < 7% 
4.2.5 Preliminary Progress/Data Report 
A logistic regression analysis was performed using data from the study of 806 drug-naive 
type 2 diabetes patients printed in the package insert (16) to determine whether there was 
an interaction effect between the 2.5mg of glyburide and 500mg ofmetformin. The likeli-
hood ratio x2 statistic associated with the test of additivity (i.e. no interaction) was 5.975, 
with a p-value of0.0145, indicating the presence of a significant interaction between the 
two drugs. In addition, the coefficient of the interaction term was negative (-0.887), indi-
eating that the interaction was antagonistic between the two drugs at the given doses . It 
should be noted that these were the starting doses given to the patients for a period of 4 
weeks, after which the dose could be increased up to a maximum of four tablets daily. 
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This initial analysis emphasizes the need for a more systematic yet flexible approach to 
combination dosing. Presumably these two drugs, glyburide and metformin, are used in 
combination with the goal that they interact synergistically, or at least in an additive fash-
ion. This analysis indicates that with the doses used in the study, the two drugs appear to 
be antagonistic to each other, rather than synergistic or additive. However, it should be 
emphasized that the combination of glyburide and metformin may be additive or synergis-
tic at dose combinations other than those used in the study. Unfortunately the design of 
the study reported does not allow the identification of other possibly more favorable 
doses. An advantage of the titration approach proposed in this study is that it will be help-
ful in identifying the dose area producing the most favorable interaction response and in 
avoiding doses where the interaction is antagonistic. 
4.2.6 Research Method and Design 
Pilot Study 
A 20 week pilot study will be conducted. Ten newly diagnosed type 2 diabetes patients, 
men and women, will be emolled using the following eligibility criteria: 
Inclusion Criteria 
Men and women newly diagnosed with type 2 diabetes and receiving no current or 
previous pharmacological treatment 
HbA1c < 10% 
Informed Consent 
Exclusion Criteria 
Women who are pregnant or nursing 
Subjects who have previously been treated with other diabetes therapies 
Subjects with hepatic or renal impairment 
(creatinine > 1.4mg/dL in women,> 1.5mg/dL in men) 
Subjects with concomitant CHF or pulmonary disease 
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Each subject will begin the study by rotating through each of three starting combi-
nations. Before beginning treatment, baseline values of fasting plasma glucose (FPG), 2-
hour postprandial plasma glucose (PPG), fingerstick HbA 10 and HbA 1 c will be recorded. 
The patient will be randomized to one of six sequences of initial dose combinations: ABC, 
ACB, BAC, BCA, CAB, or CBA where A=one 2.5mg tablet glyburide, one 500mg tablet 
metformin, B=two 2.5mg tablets of glyburide, one 500mg tablet metformin, or C=one 
2.5mg tablet glyburide, two 500mg tablets metformin. Each dose combination will be 
administered for a period of2 weeks. The patient will be instructed to keep a daily journal 
of his or her fasting glucose measurements and 2-hour postprandial glucose measure-
ments. At the end of the first treatment period and each subsequent two week period, the 
fasting glucose measurements and 2-hour postprandial glucose measurements, recorded 
by the patient over the previous one week, will be reported to and averaged by the physi-
cian, along with a fingerstick HbA1c measurement. In addition, the number ofreported 
hypoglycemic episodes and the number ofreported negative GI effects over the previous 
one week will also be recorded. Unless an office visit is requested by the patient at the end 
of each treatment period, the averaged fasting and 2-hour postprandial glucose measure-
ments, the fingerstick HbA10 the number of hypoglycemic episodes, and the number of 
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GI complaints will be reported to the physician over the telephone at the end of the second 
week. The measurements will be combined into a single desirability measure (Appendix 
4.A) and the Nelder-Mead algorithm (Appendix 4.B) will be used to determine the next 
dose combination to be administered to the patient. If the physician is uncomfortable with 
the algorithm determined dose, the physician will be permitted to adjust the dose, and the 
actual dose prescribed by the physician will be recorded, together with the algorithm 
determined dose. The following treatment dose will again be determined by the Nelder-
Mead algorithm, using the adjusted dose information. 
The study will continue for a period of20 weeks. The dose combination for each 
patient will be titrated until an average fasting glucose of < 150 or an average 2-hour post-
prandial glucose of< 180 is achieved or until the end of the study period. After a mainte-
nance dose is established, bi-monthly reports with data collection and monitoring will 
continue for the duration of the study period. 
Laboratory Studies 
BP, ALT, serum creatinine, cholesterol, HbA1c (initial and final visit), fingerstick HbA1c 
Data Collection and Monitoring 
The patient will keep a diary of daily fasting glucose and 2-hour postprandial glucose 
measurements. The measurements recorded by the patient over the previous one week 
will be averaged and recorded at each visit. Fingerstick HbA 1 c will also be measured at 
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each visit. Serum HbA 1 c will be measured at the initial visit and final visit. 
Primary Study 
Men and women with newly diagnosed type 2 diabetes will be emolled into the study and 
randomized to either the 2-drug titration group or the Glucovance group. The number of 
subjects to be emolled will be determined by the estimate of the proportion of subjects 
achieving a HbA1c < 7% after twenty weeks in the preliminary study, together with Table 
1 in the Statistical Analysis section. An estimate of the proportion of subjects achieving a 
HbA1c < 7% with Glucovance after twenty weeks has already been reported (16). Sub-
jects will be blinded as to which treatment approach they are receiving. 
Glyburide+Metformin titration group 
This group will follow the same study protocol as in the pilot study, with the exception 
that the study will continue for a period of 24 weeks. 
Glucovance Group 
Subjects will be treated using regular standard of care. The patient will be instructed to 
keep a daily journal of his or her fasting glucose measurements and 2-hour postprandial 
glucose measurements. The fasting glucose measurements and 2-hour postprandial glu-
cose measurements will be reported to the physician, along with a fingerstick HbA1c mea-
surement every two weeks. The number of reported hypoglycemic episodes and the 
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number of reported negative GI effects over the previous one week will also be recorded. 
Unless an office visit is requested by the patient at the end of each treatment period, the 
averaged fasting and 2-hour postprandial glucose measurements, the fingerstick HbA 10 
the number of hypoglycemic episodes, and the number of GI complaints will be reported 
to the physician over the telephone at the end of every other week. 
Laboratory Studies 
BP, ALT, serum creatinine, cholesterol, HbA1c (initial and final visit), fingerstick HbA1c 
Data Collection and Monitoring 
The patient will keep a diary of daily fasting glucose and 2-hour postprandial glucose 
measurements. The measurements recorded by the patient over the previous one week 
will be averaged and recorded at each visit. Fingerstick HbA1c will also be measured at 
each visit. Serum HbA1c will be measured at the initial visit and final visit. 
4.2.7 Statistical Analysis 
To test the primary hypothesis of equal proportions HbAlc < 7% between treatment 
groups, a continuity corrected x2 test will be used. 
To test the secondary hypothesis of no difference in mean desirability score 
between treatment groups, a 2-sided t-test of means will be used. 
The following table shows the sample size estimates for testing the primary 
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hypothesis of equal proportions HbA le < 7% in the group treated with a titrated combina-
tion of glyburide and metformin vs. fixed doses of Glucovance. 
Table 4.1 : N per group required for x2 test of equal proportions for two groups (continuity 
corrected) 
Powei=80% GrouE 1 Ero~ortion, 7t 1 
a=0.05 0.25 0.3 0.35 0.4 0.45 0.5 0.55 0.6 0.65 0.7 0.75 0.80 0.85 0.90 
Group 2 
proportions 
n2=0. 15 270 134 83 57 42 33 26 22 18 15 13 I I IO 9 
n2=0.20 11 34 3 13 15 1 9 1 62 45 35 28 22 19 16 13 II 10 
n2=0.25 1291 349 165 98 66 48 36 28 23 19 16 13 II 
n2=0.30 141 7 376 176 103 68 49 37 29 23 19 15 13 
n2=0.35 15 11 396 183 106 70 49 37 28 22 18 15 
n2=0.40 1574 408 186 107 70 49 36 28 22 17 
n2=0.45 1605 412 186 106 68 48 35 26 20 
n2=0.50 1605 408 183 103 66 45 33 25 
n2=0.55 1574 396 176 98 62 42 30 
n2=0.60 1511 376 165 91 57 38 
n2=0.65 141 7 349 15 1 83 5 1 
n2=0.70 129 1 313 134 72 
n2=0.75 1134 270 11 3 
n2=0.80 945 219 
n2=0.85 726 
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4.2.9 Appendices 
Appendix 4.A 
Overview of Desirability Functions I 9, 20, 21 • 22 
Each response of interest is transformed to a continuous desirability function, di , with val-
ues ranging from 0 to 1, where a value of 0 designates the response as not at all desirable, 
while a value of 1 is assigned to the most desirable response. The basic shape of the func-
tion is determined by whether one is trying to maximize or minimize the response, or aim 
for a range of target values. The exact shape of each desirability function is determined in 
collaboration with the physician or other experts knowledgeable about the disease under 
study and the therapeutic effects of the treatments being administered. The following is 
the mathematical form of a maximizing desirability function 
[ [ Y. -a.)]-1 l +exp- T 
di(max)= , where 
Y. + y' b y' -Y. y y• 
Q. = l l ' . = l I ' ·• < . 
I 2 I 2ln(l- yj ) I I 
Y; 
The parameter a; is an average of the upper (Yi*) and lower (Yi•) bounds of the response 
level being targeted, bi controls the function spread, and Yi is defined so that the desirabil-
ity at Yi* equals Yi, and the desirability at Yi* equals 1- Yi· A minimizing desirability is 
obtained by reversing the sign of the exponential argument. A target desirability function 
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can then be constructed by multiplying a minimizing (di(min)) and a maximizing (di(max)) 
desirability function such that di=di(max) *di( min)· The parameters a;, b;, and y;, allow the 
researcher flexibility in defining the desirability function and the degree of conservative-
ness to incorporate. These individual desirability functions can then be combined using 
the geometric mean to arrive at a composite measure of the overall desirability, D, such 
that D=(d1 *d2* ... *dk) l/k. It is also possible to assign different weights to the individual 
desirabilities. 
The following desirability functions will be used in the study and incorporated into a 
composite desirability measure D=(dl *d2*d3*d4*d5)115• 
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0.2 
0.1 
0.0 
70 80 90 100 110 120 130 140 150 160 17C 
Fasting Plasma Glucose (mg/dl) 
Figure 4.1. Target desirability function for fasting plasma glucose. The function is speci-
fied using the following parameters: dl(max): Y1 •' = 80, Y 1 •, = 100, y1' = 0.05, 
di(minf Y1•" = 140, Y1•,,=160, y1" = 0.05 
di= d1(max)*d1(min) 
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Figure 4.2. Target desirability function for 2-hour post-prandial plasma glucose. The func-
tion is specified using the parameters: d2(max) : Y 2.' = 80, Y 2" = 100, Y2' = 0.05, d2(min): 
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d2 = d2(max) *d2(min) 
2 3 4 5 6 7 8 9 10 11 12 13 
Fingerstick HbA 1 c (%) 
Figure 4.3. Minimizing desirability function for fingerstick HbAic· The function is speci-
fied using the parameters: d3(min): Y3• = 6, Y3 * = 10, Y3 = 0.05 
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Hypoglycemic Episodes per Week 
Figtrre 4.4. Minimizing desirability function for ntrrnber of hypoglycemic episodes per 
week. The function is specified using the parameters: d4(min): Y4• = 1, Y/ = 5, y4 = 0.05 
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Figure 4.5. Minimizing desirability function for number of gastrointestinal complaints per 
week. The function is specified using the parameters: ds(minf Y s• = 1, Y 5 * = 7, y5 = 0.05 
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Appendix 4.B 
Description of the evolutionary titration procedure using the Nelder-Mead Simplex 
procedure23 
Once the individual desirability functions are defined, they are incorporated into a com-
posite desirability function, D, which is the response undergoing optimization during the 
titration process. An evolutionary operation (EVOP)24• 25 approach is used to titrate the 
combination of drugs within each subject. The first step of the procedure is to establish an 
initial simplex, a geometric figure with a fixed number of vertices. In the two drug case, 
the simplex is a triangle. Each vertex A, B, and C, of the triangle (Figure 4.6) represents 
different dose levels of the two drug combination. At the initial step, the subject's 
response is measured at each of these three dose combinations, and the composite desir-
ability resulting from the administration of each combination is compared, with the sim-
plex reflecting away from the least desirable response, through the centroid of the face 
created by the remaining vertices to a new point, E. In addition to reflection, the simplex 
can also extend (point F), contract (points H or G), or perform a shrinkage contraction 
(points A',B', and C), depending on the contour of the response surface. The conditions 
for subsequent movement are listed in Table 4.2 and correspond to Figure 4.6. 
F 
Drug 1 
Figure 4.6: Nelder-Mead simplex ABC with possible subsequent points. 
Table 4.2. Conditions governing the formation of subsequent simplex. f(x) denotes the 
response evaluated at point x. Here a lower value represents a more favorable response. 
Adapted from Olsson and Nelson26. 
Condition Action New Simplex 
f(C) ~ f(E) ~ f(B) Reflect BCE 
f(E) < f(C) Extend BCF 
f(A) < f(E) Contract BCG 
f(B) < f(E) ~ f(A) Contract BCH 
f(A) ~ f(G) or f(E) ~ f(H) Shrink A'B'C 
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The new dose combination determined by the algorithm is not given in units of 
whole pills or whole dose units, so the dose combinations are adjusted to whole units. The 
new dose combination to be administered is determined by either rounding to the nearest 
whole pill, or more conservatively, by rounding down to the dose unit. The initial simplex 
step size, which specifies how far apart the initial dose combinations are, and the reflec-
tion and expansion coefficients used by the Nelder-Mead procedure, which determine how 
far the simplex can move or expand in one step, are decided in collaboration with the phy-
sician, and can be modified to be more or less conservative depending on factors such as 
the therapeutic index of the drug involved 
Each subject begins the process by being evaluated at each of the p+ 1 combina-
tions ofp drugs in the regimen. The subject receives the initial combination and the 
response is recorded. The subject then receives the second combination, which is deter-
mined by the initial step size, and the response is measured after a time interval sufficient 
to preclude carryover effects. This continues for each of the p+ 1 drug combinations. 
After the initial simplex is established, the new simplex is formed using the rules in Table 
4.2, determining the next dose combination to be administered. This process repeats until 
the subject has passed through a fixed number of steps or until other specific stopping cri-
teria are reached and further titration is deemed unnecessary. The simplex movement can 
be continuously monitored by the physician, and the reflection, expansion, and contraction 
coefficients can be modified ifthe simplex expands to a dose the physician is uncomfort-
able with. A dose constraint can also be put in as a boundary to prevent the simplex from 
moving above a certain dose in one or more dimensions. At the final step, the last simplex 
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is evaluated and the combination producing the most desirable response is determined to 
be the 'best' treatment combination. 
Chapter 5 
Simulation Study 
5.1 Overview of Simulation Study 
A series of simulation studies was performed to examine the effectiveness of the EVOP 
multi-drug titration algorithm in dosing a combination of therapeutic agents and to deter-
mine the effect of modifying the number of steps, the sample size, the shape of the desir-
ability function, and the initial step size. The estimated dose response surface used in the 
simulations was obtained from a published multicenter, factorial design clinical trial con-
ducted by Burris, et.ai.24, which studied the efficacy of the combination therapy of the 
diuretic hydrochlorothiazide (HCTZ) and a slow-release formulation of diltiazem hydro-
chloride (DLTZ), a calcium channel blocker, in the treatment of mild to moderate hyper-
tension. 
The trial was conducted over a period of six weeks, following a 4- to 6-week pla-
cebo 'run-in' period. A 4 by 5 factorial grid of treatment doses was used, with 4 twice-a-
day doses ofhydrochlorothiazide ranging from 0 to 25 mg, and 5 twice-a-day doses of dil-
tiazem hydrochloride ranging from 0 to 180 mg. Mild-to-moderate essential hypertension 
was defined as supine diastolic blood pressure in the range of 95 to 110 mmHg. The goal 
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of treatment was to achieve a supine diastolic blood pressure ofless than 90 mmHg, with 
no limiting adverse experience. 261 patients completed the six-week treatment protocol, 
with 13 to 17 patients randomized to each treatment group. 
Using Proc RSREG in SAS, Version 6.12 (SAS Institute, Cary, NC)25, data from 
the plots published in the study were used to generate the response surfaces for the three 
main variables of interest: diastolic blood pressure (DBP), 4.16+ 1.60xHcTZ+0.39xnLTZ-
0.12x2HcTZ+ 0.020x2nLTZ-0.033xHcTZ*xnLTz; serum cholesterol (CHO), 
0.12+0.092xHcTZ+0.033xnLTz-0.0073x2HcTZ- 0.0032x2nLTz-0.0013xHcTZ*xnLTZ; and 
serum glucose (GLU), -0.12+0.076xHcTZ-O.Ol lx0 LTz-0.0001 lx2HCTZ+ 0.0030x20 LTZ-
O.OOl lxHcTZ*xoLTZ· The dose units were converted from milligrams to whole pill 
counts. One pill was equivalent to 3.125mg ofHCTZ or 15mg ofDLTZ. 
A desirability function was defined for each of the three responses, DBP, CHO, 
and GLU. The three functions, d1-d3 (Figs 5.1-5.3), were combined into an overall 
unweighted composite desirability function, D = (d1*d2*d3) 1/ 3. The Nelder-Mead sim-
plex procedure was used to carry out the within-patient titration using the composite desir-
ability. 
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Decrease in DBP (mmHg) 
Figure 5.1: Target desirability function for diastolic blood pressure (d1). This function is a 
product of a minimizing desirability function (d1 ' )with parameters Y1 •' = 0, Y 1 •, = 10, 
y1' = 0.05, and a maximizing desirability function (d1 ")with parameters Y1." ' = 30, Y 1 •., 
= 40, Y1" = 0.05. 
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Increase in Cholesterol (mg/dL) 
Figure 5.2: Minimizing desirability function for increase in cholesterol (d2) with parame-
ters Y2• = 11.6, Y2 * = 27.1 , y2 = 0.05. 
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Figure 5.3: Minimizing desirability function for increase in serum glucose (d3) with 
parameters Y3• = 7.2, Y3 * = 14.4mmoVL, y3 = 0.05. 
5.2 Simulation Example 
For each subject, the starting dose for the initial simplex was chosen to be the same as the 
smallest combination dose used in the original study: 6.25mg (2 pills) ofHCTZ and 60mg 
(4 pills) ofDLTZ. The initial step size was chosen to be this initial dose combination 
increased by 6 pills in the HCTZ axis and by 8 pills in the DLTZ axis. 
In order to simulate subject responses more realistically, a mixed effects model 
with a first order autoregressive covariance structure was used. Let Yij=xi/P+cii' where Yij 
represents the jth response from the ith subject, xij=[ 1 xil xi2 xi12 xi/ xi1 xi2] represents the 
6x I vector of doses and dose functions for the ith subject at the jth time point, P represents 
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the 6x 1 vector of parameters taken from the study, and Eij represents the random error. 
The covariance between two observations w time intervals apart on the same subject is 
crE 2p w, where p is the correlation between adjacent observations within the same subject, 
and w is the number of time intervals between the observations. For this study, the root 
MSE for DBP, crDBP, was 6.2mmHg (pers. comm.), and 0.35mmol/L was used for both 
CHO, crc80, and GLU, crcLu· 
The simulated response at each vertex of the simplex was obtained in triplicate and 
the responses were averaged. The desirability for each averaged response was compared, 
and the location of the next dose combination to be given was determined by the Nelder-
Mead algorithm, rounding to the nearest whole pill. Figure 5.4 is an example showing the 
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DLTZ(~ills) 
Figure 5.4: Simplex movement for one subject in a two-dimensional dose space. The 
subject is evaluated at each of three initial dose combinations (1,2,3) [2 pills HCTZ/4 
pills DLTZ; 8 pills/4 pills; and 2 pills/12 pills]. The simplex reflects away from the 
combination producing the least desirable response (in this example, point 1). The final 
optimized dose combination (F) after 20 steps is 3 pills HCTZ and 19 pills DLTZ, corre-
sponding to a simulated decrease in diastolic blood pressure of 18.4mmHg 
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simplex movement for a single subject. The titration was continued for 20 steps. At the 
last step, the final simplex was evaluated and the dose combination associated with the 
most desirable response was taken as the final treatment combination. This subject 
arrived at a final dose combination of3 pills HCTZ and 19 pills DLTZ, with a simulated 
decrease in DBP of 18.4mmHg. Figure 5.5 demonstrates the simplex movement for the 
same subject starting with a smaller initial step size increase of 4 pills in the HCTZ axis 
and 6 pills in the DLTZ axis, with titration continuing for 20 steps. The final dose combi-
+ 
+ 
F 
* * 
+ + 
1) l2 20 22 24 26 
DLTZ(pills) 
Figure 5.5: Simplex movement for one subject in a two-dimensional dose space with 
smaller initial steps. The subject is evaluated at each of three initial dose combinations 
(1,2,3) similarly to above, but the initial simplex is smaller [2 pills HCTZ/4 pills DLTZ; 
6 pills/4 pills; and 2 pills/10 pills] . Note that the process ends with a combination simi-
lar to that reached above, 3 pills HCTZ and 18 pills DLTZ, corresponding to a simulated 
decrease in diastolic blood pressure of 15.7mmHg. 
nation reached was 3 pills ofHCTZ and 18 pills ofDLTZ, similar to that obtained with the 
larger step size. The corresponding decrease in DBP was 15.7mmHg. 
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Figure 5.6 demonstrates the final dose locations for a simulated group of 175 sub-
jects who have completed the titration process, and Figure 5.7 shows the asymptotic confi-
dence ellipsoid about the central location estimate for the Wilcoxon Signed Rank statistic 
and Figure 5.8 shows the confidence ellipsoid about the mean. A correlation between sue-
cessive blood pressure observations of p=0.7 was used and the process continued for 16 
steps. 
12 
Figure 5.6: Pyramid plot of final dose locations for a simulated group of 175 subjects who 
have completed the 16 steps of titration, using a correlation of0.7. In this simulation, the 
desirability function for DBP shown in Figure 5.1 was used to target a reduction in dias-
tolic blood pressure (DBP). The mean decrease in DBP was 17.7mmHg. The mean final 
dose combination was 4.6 pills HCTZ and 16.2 pills DLTZ. 
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Figure 5.7: Asymptotic confidence ellipsoid based on the Wilcoxon signed rank statistic. 
A group of 175 subjects was simulated using the desirability function for DBP in Figure 
5.1. 
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Figure 5.8: Asymptotic confidence ellipsoid based on the mean. A group of 175 subjects 
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was simulated using the desirability function for DBP in Figure 5.1. 
5.3 Simulation Results 
For the main simulation study, five groups of 100 simulations were run using sample sizes 
ofN= l 75 with 16 and 32 steps. The simulations were run first using the desirability func-
ti on for DBP alone, d1 (Fig. 5.1 ), and then repeated using the composite desirability func-
tion, D=(d1 *d2*d3) 1/ 3, which took into account serum cholesterol and serum glucose 
measurements in addition to the DBP. Additionally, to examine the effect of the correla-
tion between successive observations, p, the correlation was varied from 0.1 to 0.8. In the 
simulations with the composite desirability function, the correlation between successive 
DBP measurements was varied from 0.1 to 0.8, while the correlations for both CHO and 
GLUwere fixed at 0.7. 
5.3.1 Number of Steps and Correlation Between Successive Observations within a 
Patient 
Desirability function for diastolic blood pressure, d1 
Using the desirability function for DBP, d1, we see in Table 5.1 that the proportion 
of subjects showing improvement over the baseline was 1 (i.e. 100%) for all cases, using 
either the Fisher Sign test or the Wilcoxon Signed Rank test. All subjects also showed 
improvement when the final response was compared to the simulated response to single 
drug treatment with 25mg ofHCTZ, the highest dose used in the study. A similar result 
was seen in comparing the response to treatment with a 180mg dose ofDLTZ. The mean 
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decrease in DBP, shown in the far right column, did not appear to change as the number of 
steps was increased from 16 to 32. However, the size of the reduction in DBP did appear 
to increase as the correlation increased. Table 5.2 shows the percentage of confidence 
ellipsoids which included the origin, included the hydrochlorothiazide axis only, included 
the diltiazem axis only, or included both axes, also using the desirability for DBP alone. 
The final central dose locations for diltiazem and hydrochlorothiazide are also given in the 
far right colunms, using both the mean and the Wilcoxon Signed Rank statistics as mea-
sures of central location. Using Mardia's test, in many instances the multivariate distribu-
tion of the final dose locations for each simulation showed some departure from 
normality, suggesting the nonparametric approach to be most appropriate. As the correla-
tion was increased from 0.1 to 0.8, the simplex appeared to move further up the DLTZ 
axis, resulting in a higher final dose ofDLTZ and a tighter confidence ellipsoid. Increas-
ing the number of steps from 16 to 32 did not appear to have much effect, suggesting that 
the simplex had already arrived at a final dose after 16 steps. 
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Table 5 .1: Proportion of improved responses using the Fisher sign test or Wilcoxon 
signed-rank test. Simulations were done using the desirability function for diastolic blood 
pressure alone (d1). The mean decrease in DBP is shown in the far right column. 
HCTZ OLTZ Decrease N Steps p Baseline Alone Alone inDBP (mmHg) 
175 16 0.1 Fisher(SE) 1(0) 1(0) 1(0) 16.4 
Wilc(SE) 1(0) 1(0) 1(0) 
0.3 F isher(SE) 1(0) 1(0) 1(0) 16.8 
Wilc(SE) 1(0) 1(0) 1(0) 
0.5 Fisher(SE) 1(0) 1(0) 1(0) 16.9 
Wilc(SE) 1(0) 1(0) 1(0) 
0.7 Fisher(SE) 1(0) 1(0) 1(0) 17.7 
Wil c(SE) 1(0) 1(0) 1(0) 
0.8 Fisher(SE) 1(0) 1(0) 1(0) 18.6 
Wilc(SE) 1(0) 1(0) 1(0) 
32 0.1 Fisher(SE) 1(0) 1(0) 1(0) 16.3 
Wilc(SE) 1(0) 1(0) 1(0) 
0.3 Fisher(SE) 1(0) 1(0) 1(0) 16.9 
Wilc(SE) 1(0) 1(0) 1(0) 
0.5 Fisher(SE) 1(0) 1(0) 1(0) 17.1 
Wilc(SE) 1(0) 1(0) 1(0) 
0.7 Fisher(SE) 1(0) 1(0) 1(0) 18.2 
Wilc(SE) 1(0) 1(0) 1(0) 
0.8 Fisher(SE) 1(0) 1(0) 1(0) 18.6 
Wilc(SE) 1(0) 1(0) 1(0) 
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Table 5.2: Evaluation of the confidence ellipsoids using a parametric and nonparametric 
approach. Simulations were done using the desirability function for diastolic blood 
pressure alone ( d 1). The columns show the percentage of confidence ellipsoids containing 
the origin, containing the HCTZ axis only, containing the DLTZ axis only, or containing 
both axes. The rightmost columns show the final dose locations for HCTZ and DLTZ 
using either the mean or Wilcoxon signed-rank statistic as the measure of central location. 
HCTZ DLTZ Final Final N Steps p Origin Axis Only Axis Only Both Axes Dose Dose HCTZ DLTZ 
175 16 0.1 Mean(SE) 0 0 97.2(1.30) 2.8(1.30) 4.5(0.03) 14.0(0.02) 
Wile(SE) 1.6(1.52) 13.4(2.92) 39.0(2.92) 23.2(4.97) 4.4(0.03) 14.2(0.03) 
0.3 Mean(SE) 0 0 99.6(0.89) 0.4(0.89) 4.5(0.02) 14.5(0.01) 
Wile(SE) 0.8(0.45) 9.6(2.70) 43.4(4.22) 16.2(3.27) 4.4(0.03) 14.7(0.01) 
0.5 Mean(SE) 0 0 100 0 4.5(0.02) 15.2(0.02) 
Wi lc(SE) 0 4.8(1.92) 51.2(5.12) 8.2(2.17) 4.4(0.02) 15.5(0.03) 
0.7 Mean(SE) 0 0 100 0 4.6(0.02) 16.2(0.02) 
Wilc(SE) 0 0.4(0.89) 64.6(5.50) 0.4(0.89) 4.5(0.02) 16.6(0.03) 
0.8 Mean(SE) 0 0 100 0 4.6(0.02) 17.1(0.02) 
Wile(SE) 0 0 68.0(3.94) 0 4.5(0.03) 17.3(0.03) 
32 0.1 Mean(SE) 0 0 99.4(0.55) 0.6(0.55) 4.4(0.01) 14.2(0.05) 
Wile(SE) 0.6(0.55) I 0.8(4.87) 49.4(4.10) 21.8(4.44) 4.2(0.02) 14.4(0.05) 
0.3 Mean(SE) 0 0 100 0 4.4(0.01) 14.7(0.06) 
Wile(SE) 0.2(0.45) 8.2(0.84) 54.0(3.87) 17.6(2.30) 4.3(0.02) 15.0(0.07) 
0.5 Mean(SE) 0 0 100 0 4.4(0.02) 15.3(0.03) 
Wile (SE) 0 2.6(1.14) 61.4(8.88) 5.6(1.95) 4.3(0.02) 15.7(0.02) 
0.7 Mean (SE) 0 0 100 0 4.5(0.02) 16.4(0.01) 
Wile (SE) 0 0 71.0(3.87) 0 4.4(0.02) 16.7(0.02) 
0.8 Mean(SE) 0 0 100 0 4.5(0.004) 17.1(0.04) 
Wile (SE) 0 0 75.4(2.30) 0 4.4(0.01) 17.4(0.05) 
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Composite desirability function, D 
The simulations were then repeated using the composite desirability function, D, 
which combined the main outcome of interest, diastolic blood pressure, with two other 
endp'oints which the study authors reported on, serum glucose and serum cholesterol. In 
these simulations, the correlation between successive DBP measurements within a patient 
was increased from 0.1 to 0.8, while the correlations for both CHO and GLU were fixed at 
0.7. Tables 5.3 and 5.4, show that the simplex does not move as far along the HCTZ axis 
or DL TZ axis when these other endpoints are taken into consideration, indicating that one 
or both of these endpoints are acting as constraints. However, from Table 5.3, we see that 
even at these doses, there is still a significant improvement in the response for all subjects 
in all cases. 
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Table 5.3: Proportion of improved responses using the Fisher sign test or Wilcoxon 
signed-rank test. Simulations were done using the composite desirability function (D). 
The correlation between successive DBP measurements was varied from 0. 1 to 0.8, while 
the correlations for both CHO and GLU were fixed at 0.7. The rightmost columns show 
the mean decrease in diastolic blood pressure, the mean change in cholesterol and the 
mean change in serum glucose. 
HCTZ DLTZ Decrease Change Change in N Steps p Baseline Alone Alone inDBP in Chol Glu (rnmHg) (mmol/L) (rnmol/L) 
175 16 0.1 Fisher (SE) 1(0) 1(0) 1(0) 11.9 0.24 0.29 
Wilc(SE) 1(0) 1(0) 1(0) 
0.3 Fisher (SE) 1(0) 1(0) 1(0) 11.9 0.25 0.29 
Wilc(SE) 1(0) 1(0) 1(0) 
0.5 Fisher (SE) 1(0) 1(0) 1(0) 11.9 0.25 0.3 1 
Wile (SE) 1(0) 1(0) 1(0) 
0.7 Fisher (SE) 1(0) 1(0) 1(0) 12.0 0.24 0.29 
Wile (SE) 1(0) 1(0) 1(0) 
0.8 Fisher (SE) 1(0) 1(0) 1(0) 12. 1 0.24 0.27 
Wile (SE) 1(0) 1(0) 1(0) 
32 0. 1 Fisher (SE) 1(0) 1(0) 1(0) 11.3 0.25 0.27 
Wi le (SE) 1(0) 1(0) 1(0) 
0.3 Fisher (SE) 1(0) 1(0) 1(0) 11.3 0.27 0.26 
Wi lc(SE) 1(0) 1(0) 1(0) 
0.5 Fisher (SE) 1(0) 1(0) 1(0) 11.6 0.25 0.3 1 
Wile (SE) 1(0) 1(0) 1(0) 
0.7 Fisher (SE) 1(0) 1(0) 1(0) 11.9 0.24 0.27 
Wile (SE) 1(0) 1(0) 1(0) 
0.8 Fisher (SE) 1(0) 1(0) 1(0) 11. 8 0.23 0.27 
Wilc(SE) 1(0) 1(0) 1(0) 
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Table 5.4: Evaluation of the confidence ellipsoids using a parametric and nonparametric 
approach. Simulations were done using the composite desirability function (D). The 
correlation between successive DBP measurements was varied from 0.1 to 0.8, while the 
correlations for both CHO and GLU were fixed at 0.7. The columns show the percentage 
of confidence ellipsoids (SE) containing the origin, containing the HCTZ axis only, 
containing the DLTZ axis only, or containing both axes. The rightmost columns show the 
final dose locations for HCTZ and DLTZ using either the mean or Wilcoxon signed-rank 
statistic as the measure of central location. 
HCTZ OLTZ Axis Final Final N Steps p Origin Axis Only Both Axes Dose Dose Only HCTZ OLTZ 
175 16 0.1 Mean (SE) 0 0 34.0(5.70) 66.0(5 .70) 3.1(0.02) 9.2(0.02) 
Wi lc (SE) 9.0(1.41) 0 61.4(2.07) 38.6(2.07) 3.0(0.02) 9.2(0.02) 
0.3 Mean (SE) 0 0 35.6(3.05) 64.4(3.05) 3.1(0.02) 9.2(0.02) 
Wile (SE) 8.8(4.92) 0 60.8(4.32) 39.2(4.32) 3.0(0.02) 9.3(0.03) 
0.5 Mean (SE) 0 0 38.2(4.44) 61.8(4.44) 3.1(0.02) 9.3(0.02) 
Wilc(SE) 9.8(2.28) 0 61.4(2.70) 38.6(2.70) 3.0(0.02) 9.4(0.02) 
0.7 Mean (SE) 0 0 44.0(5.24) 56.0(5.24) 3.1 (0.02) 9.4(0.02) 
Wilc(SE) 8.8(3.27) 0 61.4(5.77) 38.6(5.77) 3.0(0.0 1) 9.5(0.02) 
0.8 Mean (SE) 0 0 51.4(3.58) 48.6(3.58) 3.1(0.02) 9.5(0.02) 
Wile (SE) 9.2(2.17) 0 59.8(4.21) 40.2(4.21) 3.0(0.02) 9.6(0.03) 
32 0.1 Mean (SE) 0 0 36.4(3. 71) 63.6(3.71) 3.0(0.02) 9.2(0.03) 
Wilc(SE) 9.2(1.64) 0 59.2(5.26) 40.8(5.26) 2.8(0.03) 9.3(0.03) 
0.3 Mean (SE) 0 0 38.6(3.78) 61.4(3.78) 3.0(0.02) 9.2(0.04) 
Wile (SE) 6.4(1.67) 0 56.4(3.13) 43.6(3. 13) 2.8(0.02) 9.3(0.04) 
0.5 Mean (SE) 0 0 40.8(3.56) 59.2(3.96) 3.0(0.01) 9.3(0.05) 
Wilc(SE) 5.2(2.05) 0 55.0(3.39) 45 .0(3.39) 2.8(0.01) 9.4(0.05) 
0.7 Mean (SE) 0 0 48.6(4. 16) 51.4(4.16) 2.9(0.01) 9.4(0.03) 
Wilc(SE) 7.0(2.55) 0 59.4(2.07) 40.6(2.07) 2.8(0.02) 9.5(0.03) 
0.8 Mean (SE) 0 0 54.2(1.92) 45 .8( 1.92) 2.9(0.01) 9.5(0.04) 
Wi lc(SE) 6.8(2.17) 0 53.0(3.54) 47.0(3.54) 2.8(0.02) 9.6(0.04) 
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5.3.2 Initial Step Size 
Tables 5.5 and 5.6 show the results of changing the initial step size from an increase of 6 
pills in the HCTZ axis and 8 pills in the DLTZ axis, to an increase of only 5 pills/7 pills, or 
4 pills/6 pills over the initial dose combination. After 16 steps, using the desirability func-
tion for DBP, a correlation of 0.7, and a sample size of 175, there was a slightly smaller 
decrease in the DBP response. In addition, the final dose combinations also decreased as 
the initial step size became smaller. This would suggest that either the simplex has not 
had enough time to reach the same improved dose as with the larger step size, or perhaps 
the simplex has reached a plateau and the variability is too large for it to move further 
along the dose response surface. 
Table 5.5: A comparison of initial step sizes. Simulations were done using the desirability 
function for diastolic blood pressure alone (d1), with 16 steps, p=0.7. The table shows the 
proportion of improved responses using the Fisher sign test or the Wilcoxon signed-rank 
test. The effect of decreasing the initial step size is shown, with the mean decrease in 
diastolic blood pressure given in the rightmost column. 
Step Size 
HCTZ OLTZ Decrease (pills HCTZ/ Baseline Alone Alone in DBP pills OLTZ) (mmHg) 
+61+8 Fisher (SE) 1(0) 1(0) 1(0) 17.7 
Wilc(SE) 1(0) 1(0) 1(0) 
+5/+7 Fisher (SE) 1(0) 1(0) 1(0) 16.7 
Wile (SE) 1(0) 1(0) 1(0) 
+4/+6 Fisher (SE) 1(0) 1(0) 1(0) 16.5 
Wile (SE) 1(0) 1(0) 1(0) 
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Table 5.6: A comparison of initial step sizes. Simulations were done using the desirability 
function for diastolic blood pressure alone (d1), with 16 steps, p=0.7. The columns show 
the percentage of confidence ellipsoids (SE) containing the origin, containing the HCTZ 
axis only, containing the DLTZ axis only, or containing both axes. The effect of 
decreasing the initial step size is shown, with the rightmost columns giving the final dose 
locations for HCTZ and DLTZ using either the mean or Wilcoxon signed-rank statistic as 
the measure of central location. 
Step Size 
HCTZ OLTZ Final Dose Final Dose (pills HCTZ/ Origin 
Axis Only Axis Only Both Axes HCTZ OLTZ pillsDLTZ) 
+6/+8 Mean(SE) 0 0 100 0 4.6(0.02) 16.2(0.02) 
Wilc(SE) 0 0.4(0.89) 64.6(5.50) 0.4(0.89) 4.5(0.02) 16.6(0.03) 
+5/+7 Mean(SE) 0 0 100 0 4.5(0.01) 15.2(0.05) 
Wilc(SE) 0 6.8(2.59) 55.4(5.18) 16.0(4.18) 4.4(0.02) 15.5(0.06) 
+41+6 Mean (SE) 0 0 90.4(1.95) 9.6(1.95) 4.2(0.02) 13.7(0.04) 
Wile (S E) 4.2(2.77) 74(2.61) 49.2(2.59) 30.4(4.62) 4.1(0.02) 13.9(0.04) 
5.3.3 Sample Size 
Tables 5.7 and 5.8 display the results of changes to the sample size. Simulations were run 
with sample sizes of25, 50, 175, and 300 subjects, using the desirability function for DBP 
alone. The between-observations correlation was fixed at 0.7, and the titration was contin-
ued for 16 steps. In general, changes to the sample size did not appear to significantly 
affect the outcomes. 
In Table 5.7, the decrease in the DBP remains similar across cases and there is a 
significant improvement in the response for all cases. In Table 5.8, the final dose combi-
nations also remain similar across the cases. 
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Table 5.7: Sample size comparison. Simulations were done using the desirability function 
for diastolic blood pressure alone ( d 1), with 16 steps, p=0.7. The table shows the 
proportion of improved responses using the Fisher sign test or the Wilcoxon signed-rank 
test. The effect of increasing the sample size is shown, with the mean decrease in diastolic 
blood pressure given in the rightmost column. 
Sample HCTZ DLTZ Decrease Baseline inDBP Size Alone Alone (mmHg) 
25 Fisher (SE) 1(0) 1(0) 1(0) 18.2 
Wilc(SE) 1(0) 1(0) 1(0) 
50 Fisher (SE) 1(0) 1(0) 1(0) 16.6 
Wile (SE) 1(0) 1(0) 1(0) 
175 Fisher (SE) 1(0) 1(0) 1(0) 17.7 
Wile (SE) 1(0) 1(0) 1(0) 
300 Fisher (SE) 1(0) 1(0) 1(0) 17.7 
Wi lc(SE) 1(0) 1(0) 1(0) 
Table 5.8: Sample size comparison. Simulations were done using the desirability function 
for diastolic blood pressure alone (d1), with 16 steps, p=0.7. The columns show the 
percentage of confidence ellipsoids (SE) containing the origin, containing the HCTZ axis 
only, containing the DLTZ axis only, or containing both axes. The effect of decreasing 
the initial step size is shown, with the rightmost columns giving the final dose locations 
for HCTZ and DLTZ using either the mean or Wilcoxon signed-rank statistic as the 
measure of central location. 
Sample Origin HCTZ OLTZ Both Axes Final Dose Final Dose Size Axis Only Axis Only HCTZ DLTZ 
25 Mean (SE) 0.6(0.89) 0 95.0(1.87) 3.6(1.52) 4.6(0.04) 16.3(0.08) 
Wile (SE) 0.6(0.89) 0.4(0.54) 91.8(1.64) 3.4(0.89) 4.5(0.04) 16.6(0.09) 
50 Mean (SE) 0 0 99.6(0.55) 0.4(0.55) 4.6(0.06) 16.3(0.06) 
Wilc(SE) 0 0.2(0.45) 84.0(2.24) 1.0(1.22) 4.4(0.06) 16.6(0.06) 
175 Mean (SE) 0 0 100 0 4.6(0.02) 16.2(0.02) 
Wile (SE) 0 0.4(0.89) 64.6(5.50) 0.4(0.89) 4.5(0.02) 16.6(0.03) 
300 Mean (SE) 0 0 100 0 4.6(0.06) 16.3(0.06) 
Wi lc(SE) 0 0 97.2(1.10) 2.8(1.10) 4.5(0.01) 16.6(0.01) 
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5.3.4 Variation in the Desirability Function 
We were also interested in determining how sensitive the titration method was to 
variability in the chosen desirability function. To determine whether small modifications 
in the desirability function had any effect on the resulting dose locations and responses, 
we ran simulations using three modified desirability functions in addition to d1, the desir-
ability function for DBP, with 16 steps, a correlation of0.7, and a sample size of 175. 
Tables 5.9 and 5.10 show that sharpening the peak desirability as with d3 , increasing the 
width of the desirability function as with db, or decreasing the width and sharpening the 
peak simultaneously as with d0 did not result in any appreciable change in the outcome 
with respect to either response or dose location. There was little or no change in the 
decrease in DBP or final dose combinations, indicating that the process is robust, or rela-
tively insensitive, to small changes in the definition of the desirability function. So while 
the desirability function has to be defined carefully, there is some room for variation when 
deciding on the parameters. 
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Table 5.9: A comparison of desirability functions. The table shows the proportion of 
improved responses using the Fisher sign test or the Wilcoxon signed-rank test. The 
parameters for the modified desirability functions are shown, with the mean decrease in 
diastolic blood pressure given in the rightmost column. 
N= l75 HCTZ OLTZ Decrease 
Dsbl Steps= l6 (Y;o' ,Y( ') (Y;o'',Y;"') Baseline Alone Alone in DBP p=0.7 (mrnHg) 
d1 Fi sher (SE) (0,10) (30,40) 1(0) 1(0) 1(0) 17.7 
Wile (SE) 1(0) 1(0) 1(0) 
da Fisher (SE) (0,20) (20,40) 1(0) 1(0) 1(0) 17.5 
Wi lc(SE) 1(0) 1(0) 1(0) 
db Fisher (SE) (-5,10) (30,45) 1(0) 1(0) 1(0) 17.5 
Wilc(SE) 1(0) 1(0) 1(0) 
de Fisher (SE) (10,20) (20,30) 1(0) 1(0) 1(0) 17.5 
Wile (SE) 1(0) 1(0) 1(0) 
Table 5.10: A comparison of desirability functions . The columns show the percentage of 
confidence ellipsoids (SE) containing the origin, containing the HCTZ axis only, 
containing the DL TZ axis only, or containing both axes. The parameters for the modified 
desirability functions are shown, with the rightmost columns giving the final dose 
locations for HCTZ and DLTZ using either the mean or Wilcoxon signed-rank statistic as 
the measure of central location. 
N=l75 HCTZ OLTZ Both Final Final Dose Dsbl Steps= l6 (Y;•,Y;") (Y;•",Y;"') Origin Axis Only Ax is Only Axes Dose OLTZ p=0.7 HCTZ 
d1 Mean (SE) (0,10) (30,40) 0 0 100 0 4.6(0.02) 16.2(0.02) 
Wilc(SE) 0 0.4(0.89) 64.6(5.50) 0.4(0.89) 4.5(0.02) 16.6(0.03) 
da Mean (SE) (0,20) (20,40) 0 0 100 0 4.6(0.0 1) 16.3(0.03) 
Wilc(SE) 0 0.2(0.45) 64.0(3.81) 0.2(0.45) 4.5(0.02) 16.6(0.04) 
db Mean (SE) (-5,10) (30,45) 0 0 100 0 4.6(0.02) 16.3(0.02) 
Wilc(SE) 0 0.4(0.55) 66.8(3 .90) 0.4(0. 89) 4.4(0.03) 16.6(0.04) 
de Mean (SE) (10,20) (20,30) 0 0 100 0 4.6(0.01) 16.3(0.02) 
Wi lc(SE) 0 0.2(0.45) 63.6(3.44) 0.2(0.45) 4.5(0.02) 16.6(0.04) 
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From our simulations, it appears that the evolutionary simplex approach is effec-
tive in arriving at dose combinations which yield improved responses in patients who are 
being treated with a combination of multiple therapies, although inferences on the location 
do not appear to be as sharp as inferences on the response. In comparing the simulation 
results with the original response data, the final dose locations were found to correspond 
well with the area of higher response seen in the Burris study24. 
Chapter 6 
Summary 
The goal of our research has been to demonstrate a method for titrating multiple drug 
combinations within individual patients and to develop the corresponding statistical meth-
odology for evaluating whether the titrated treatment combination has resulted in an 
improvement in patient response and whether a therapeutic synergism exists. An evolu-
tionary operation direct-search procedure is used to titrate a combination of agents within 
individual subjects. Desirability functions are incorporated to define the main response of 
interest and additional responses or constraints. 
This approach permits every patient the potential to benefit from the combination 
under study and allows the consideration of multiple endpoints and constraints. It is well 
suited to the treatment of chronic diseases with long courses where there is a rapidly and 
easily measured response, where regular treatment intervals exist, and where dose escala-
tion within a patient is reasonable. Practicing physicians may find this approach useful for 
.improving the way both mono-therapies and combination therapies are prescribed for 
individual patients. Clinical researchers may find this methodology useful for evaluating 
whether a therapeutic synergism exists within specific drug combinations and for evaluat-
ing individual therapeutic components. 
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Appendix A 
Computer Programs 
The main computer programs used to perform the evolutionary operation direct-search 
titration procedure in the simulation studies are provided in this appendix. All programs 
were written in SAS®, version 6.12, for Windows. The programs are a compilation of 
code written by the author, Chris Ge1U1ings, and Vernon Chinchilli . 
Program NEWDSBSIM 
********************************************* ***** 
* 
* 
* 
* 
THIS PROGRAM USES THE NELDER-MEAD ALGORITHM 
AND DESIRABILITY FUNCTIONS TO MINIMIZE A 
GIVEN FUNCTION. IT INVOKES THE PROGRAMS 
SIMPLEX AND RANK LOC 
* 
* 
* 
* 
*************************** *************** *** *** *• 
' 
goptions ftext=centb colors=(blue) ; 
Ill 
*GOPTIONS ftext=centb NODISPLAY NOPROMPT DEVICE=cgmmw6c GSFMODE=replace 
colors=(blue) GSFNAME=PICnm; 
OPTIONS LINESIZE=BO; 
DATA ONE; 
* diastolic bp surface; 
XO= 4.16; x1=1.60; x2 = 0 .39; x1sq=-0 . 12; x2sq=.020; x1 x2 = -0.033; 
*to adjust to units of pills (hctz 1 pill=3 . 125 mg, dlt 1 pill=15 mg); 
* change in serum chol surface; 
zO = .12; z1=.092; z2=.033; z1sq= - .0073; z2sq= - .0032; z1z2=-.0013; 
*change in serum glucose surface; 
wo = -0.12; w1=0.076; w2=-0 . 011; w1sq=-0 . 00011; w2sq=0.0030; w1w2=-
0.0011; 
PROC !ML; 
USE ONE; READ ALL VAR{XO X1 X2 x1sq x2sq X1X2} INTO XX; 
READ ALL VAR{zO z1 z2 z1sq z2sq z1z2} INTO z; 
READ ALL VAR{wO w1 w2 w1sq w2sq w1 w2} INTO w; 
PRINT 'Regressions Coefficients', 'for diastolic bp' XX, 
'for serum cholesterol' z, 
'for serum glucose' w; 
NITER =16 · 
- - ' 
sig_tot 6.2; 
sig_chl .35; 
sig_glu = .35; 
print _NITER_, sig_tot sig_chl sig_glu; 
%include simprank; 
rho_bp=0.1; rho_chl=0.7; rho_glu=0.7; 
print rho_bp rho_chl rho_glu; 
sigvec=sig_totl lsig_chll lsig_glu; 
rhovec=rho_bpl lrho_chll lrho_glu; 
numvars=3; 
numcol=_NITER_+2; 
do c=1 to numvars; 
do row=1 to (numcol); 
do col=1 to (numcol); 
if abs(col-row)<=10 then; 
pwr=abs(col-row); 
else pwr=10; 
tempr=tempr 11 ( rhovec [ c J ##pwr); 
end; 
temp2=temp2//tempr; 
free tempr; 
end; 
temp3=root(temp2); 
thalf_r=(sigvec[c])#temp3; 
half_r=half_r//thalf_r; 
free temp2 temp3 thalf _r; 
end; 
START FUNCTION; 
* parms = int(parms); *rounding down to an integer; 
parms = round(parms); *rounding to the nearest integer; 
* ti tle4 
title4 
BETA = 
'Rounding down doses (in units of pills) to an integer' ; 
'Rounding doses (in units of pills) to nearest integer'; 
II PARMS[1,J II parms[2,J II PARMS[1,]##2 II PARMS[2,]##2 
I I PARMS[1,]#PARMS[2,J; 
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parms1 beta[2]; 
parms2 beta[3]; 
TEMP=O; TEMPC=O; TEMPG=O; 
DO J 1 TO 3; 
response= BETA*XX ' + part_a[j,i]; 
temp = temp+response; 
END; 
BP VALUE TEMP / 3; 
CN VALUE BETA*Z ' + part_b[i_b]; 
GN VALUE BETA*w ' + part_g(i_g]; 
* setup desirability functions; 
y1L1=0; y1U1=10; y1L2=30; y1U2=40; gamma1=0 . 05; 
a11=(y1L1+y1U1) / 2; b11=(y1U1-y1L1) / (2#log((1-gamma1) / gamma1)); 
a12=(y1L2+y1U2) / 2; b12=(y1U2-y1L2) / (2#log((1-gamma1) / gamma1)); 
d11=(1+exp(-(bp_value -a11) / b11))##(-1); 
d12=(1+exp((bp_value-a12) / b12))##(-1); 
d1=d11#d12; 
y2L=0.3; y2U=0.7; gamma2=0.05; 
a2=(y2L+y2U) / 2; b2=(y2U-y2L) / (2#log((1-gamma2) / gamma2)); 
d2=(1+exp((cn_value-a2) / b2))##(-1); 
y3L=0.4; y3U=0.8; gamma3=0.05; 
a3=(y3L+y3U) / 2; b3=(y3U-y3L) / (2#log((1-gamma3) / gamma3)); 
d3=(1+exp((gn_value-a3) / b3))##(-1); 
* overall desireability function; 
D = (d1#d2#d3)##(1/3); 
*d=d1; 
*d=d2; 
*d=d3; 
CONSTANT = O; 
IF PARMS[1,] > 16 THEN CONSTRNT=1; 
IF PARMS[2,] > 24 THEN CONSTRNT=1; 
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IF PARMS[1,] < 0 THEN CONSTRNT=1; 
IF PARMS[2,] < 0 THEN CONSTRNT=1; 
IF CONSTANT = 1 THEN fn_value = 9999999; 
ELSE IF CONSTANT = 0 THEN fn value = -D; 
i=i+1; i_b=i_b+1; i_g=i_g+1; 
FINISH; 
START SIMULATE; 
DO SAMPLE 1 TO 175; 
PARMS= 0 II O; 
z_a=normal(j(numcol,numvars,21435)); 
do rows_a=1 to 3; 
temp_a=z_a[,rows_a]'*half_r[1 :numcol,J; 
part_a=part_alltemp_a; 
end; 
z_b=rannor(j(numcol,1,34323)); 
part_b=z_b'*half_r[(numcol+1): (2*numcol),J; 
z_g=rannor(j(numcol,1,32995)); 
part_g=z_g'*half_r[(2*numcol+1):(3*numcol),J; 
i=1; i _b=1; i _g=1; 
run function; * print parms fn value en value gn_value; 
fOO_valu=-fn_value; 
i=1; i_b=1; i_g=1; 
parms = 01112; 
run function; * print parms fn value en value gn_value; 
f _O_x2a = -fn_value; 
i=1; i_b=1; i_g=1; 
parms = 011 24; 
run function; * print pa rms fn value cn_value; 
f o x2b = -fn_value; 
i=1; i_b=1 ; i_g=1 ; 
parms = Bll O; 
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run function; * print parms fn value cn_value gn_value; 
f_x1a_o = -fn_value; 
i=1; i_b=1; i_g=1; 
parms = 16//0; 
run function; * print parms fn value cn_value; 
f x1b O = -fn_value; 
i=1; i_b=1; i_g=1; 
in_parms 2//4; *in units of pills; 
in_ steps in_parms+4; 
RUN SIMPLEX; 
FO_VALUE=-FO_VALUE; 
FN_VALUE=-FN_VALUE; 
RESULTS = RESULTS II (SAMPLE 11 PARMS ' 11 f _x1 a_o 11 f x1 b o 1 1 
f _O_x2a I I f_O_x2b 
I I FOO_VALU I I FN_VALUE 
I lbp_valuel lcn_valuel lgn_value l I COUNT); 
FREE FO VALUE FN VALUE part a fn vec z_b z_g; 
END; 
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res lab 
'FUNCTN O' 
{'SAMPLE' 'X1' ' X2' ' f_x1a_O' 'f_x1b_O' 'f_O_x2a' ' f_O_x2b' 
'FUNCTION' 'DECR_BP (mmHg)' 'CHG_cho (mmol / L)' ' CHG_gl u 
( mmol IL) ' 'COUNT' } ; 
* 
* 
CREATE RESULTS FROM RESULTS[COLNAME=RESLAB]; 
APPEND FROM RESULTS; 
FINISH; 
START IMPROVE; 
PLACE=NCOL(RESULTS); 
Y = RESULTS[,PLACE-4]-RESULTS[,PLACE-5]; 
DEN = NROW(Y); 
TPLUS = SUM((Y>O)#RANKTIE(ABS(Y) )); 
TJ = DESIGN(RANKTIE(Y))[+,]; 
VAR_T = (DEN#(DEN+1)#(2#DEN+1)-.5#SUM(TJ#(TJ-1)#(TJ+1))) / 24; 
ties= (den#(den+1)#(2#den+1))/24; 
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if var_t '=ties then print group simul 'ties occur' var_t ties; free 
ties; 
* 
* 
TSTAR = (TPLUS-(DEN#(DEN+1) / 4})/SQRT(VAR_T); 
PVALUE=1-PROBNORM(TSTAR); 
IF PVALUE > .05 THEN TSTRTEST=O; ELSE TSTRTEST=1; 
PRINT 'WILCOXON SIGN RANK TEST:' TSTAR PVALUE; 
BSTAR = NCOL(LOC(Y>O)); 
PVALUEB = 1-PROBBNML(.5,DEN,BSTAR); 
IF PVALUEB > . 05 THEN BSTRTEST=O; ELSE BSTRTEST=1; 
PRINT 'FISHERS SIGN TEST: ' BSTAR DEN PVALUEB; 
free y tplus tj var_t 
Y = RESULTS[,PLACE-4]-RESULTS[,PLACE-6]; 
TPLUS = SUM((Y>O)#RANKTIE(ABS(Y))); 
TJ = DESIGN(RANKTIE(Y))[+,]; 
VAR_T = (DEN#(DEN+1)#(2#DEN+1)-.5#SUM(TJ#(TJ -1)#(TJ+1))) / 24; 
ties= (den#(den+1)#(2#den+1))/24; 
if var_t '=ties then print group simul 'ties occur' var_t ties; free 
ties; 
TSTAR2b = (TPLUS-(DEN#(DEN+1)/4))/SQRT(VAR_T); 
PVALUE=1-PROBNORM(TSTAR2b); 
IF PVALUE > .05 THEN TSTRTS2b=O; ELSE TSTRTS2b=1; 
BSTAR2b = NCOL(LOC(Y>O)); 
PVALUEB = 1-PROBBNML(.5,DEN,BSTAR2b); 
IF PVALUEB > .05 THEN BSTRTS2b=O; ELSE BSTRTS2b=1; 
free y tplus tj var_t; 
Y = RESULTS[,PLACE -4] -RESULTS[,PLACE-7]; 
TPLUS = SUM((Y>O)#RANKTIE(ABS(Y))); 
TJ = DESIGN(RANKTIE(Y))[+,]; 
VAR_T = (DEN#(DEN+1)#(2#DEN+1)-.5#SUM(TJ#(TJ-1)#(TJ+1))) / 24; 
ties= (den#(den+1)#(2#den+1)) / 24; 
if var_t ' =ties then print group simul 'ties occur' var_t ties; free 
ties; 
TSTAR2a = (TPLUS-(DEN#(DEN+1) / 4))/SQRT(VAR_T); 
PVALUE=1-PROBNORM(TSTAR2a); 
IF PVALUE > .05 THEN TSTRTS2a=O; ELSE TSTRTS2a=1; 
BSTAR2a = NCOL(LOC(Y>O)); 
PVALUEB = 1-PROBBNML(.5,DEN,BSTAR2a); 
IF PVALUEB > .05 THEN BSTRTS2a=O; ELSE BSTRTS2a=1; 
free y tplus tj var_t; 
Y = RESULTS[,PLACE-4]-RESULTS[,PLACE-8]; 
TPLUS = SUM((Y>O)#RANKTIE(ABS(Y))); 
TJ = DESIGN(RANKTIE(Y))[+,]; 
VAR_T = (DEN#(DEN+1)#(2#DEN+1)-.5#SUM(TJ#(TJ-1)#(TJ+1)))/24; 
ties= (den#(den+1)#(2#den+1))/24; 
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if var_t '=ties then print group simul 'ties occur' var_t ties; free 
ties; 
TSTAR1b = (TPLUS-(DEN#(DEN+1)/4))/SQRT(VAR_T); 
PVALUE=1-PROBNORM(TSTAR1b); 
IF PVALUE > .05 THEN TSTRTS1b=O; ELSE TSTRTS1b=1; 
BSTAR1b = NCOL(LOC(Y>O)); 
PVALUEB = 1-PROBBNML(.5,DEN,BSTAR1b); 
IF PVALUEB > .05 THEN BSTRTS1b=O; ELSE BSTRTS1b=1; 
free y tplus tj var_t; 
Y = RESULTS[,PLACE-4]-RESULTS[,PLACE-9]; 
TPLUS = SUM((Y>O)#RANKTIE(ABS(Y))); 
TJ = DESIGN(RANKTIE(Y))[+,]; 
VAR_T = (DEN#(DEN+1)#(2#DEN+1) - .5#SUM(TJ#(TJ-1)#(TJ+1))) / 24; 
ties= (den#(den+1)#(2#den+1))/24; 
if var_t ' =ties then print group simul 'ties occur' var_t ties; free 
ties; 
TSTAR1a = (TPLUS-(DEN#(DEN+1)/4))/SQRT(VAR_T); 
PVALUE=1 -PROBNORM(TSTAR1a); 
IF PVALUE > .05 THEN TSTRTS1a=O; ELSE TSTRTS1a=1; 
BSTAR1a = NCOL(LOC(Y>O)); 
PVALUEB = 1-PROBBNML(.5,DEN,BSTAR1a); 
IF PVALUEB > .05 THEN BSTRTS1a=O; ELSE BSTRTS1a=1; 
free y tplus tj var_t; 
FREE DEN y TJ VAR T TPLUS PLACE ties; 
FINISH; 
start thersyn; 
* CRITICAL VALUE FROM CHI SQUARE DISTN WITH P OF, ALPHA=.05; 
_CHI_ = 5.99; 
ddf = nrow(x)-p; 
_F_= finv( . 95,p,ddf); 
fcrit (_num_-1)*p/(_num_-p)*_f_; 
MAXX1 = X[<>,1] + 5; 
MAXX2 = X[<>,2] + 5; 
RX1 MAXX1 /30; 
RX2 MAXX2/30; 
if simul=1 then do; 
wconfO=O; wconf1=0; wconf2=0; wconf12=0; wconfts=O; 
mconfO=O; mconf1=0; mconf2=0; mconf12=0; mconfts=O; 
end; 
wflag1=0; wf lag2=0; 
mflag1=0; mflag2=0; 
* checking origin; 
Z1 
z2 
o· 
' 
o· 
' 
_THETA_= Z1 // Z2; 
WIL (WILCOXON-_THETA_)'*INV(TAU_W)*(WILCOXON-_THETA_); 
MU (XBAR-_THETA_) '* INV(SIGMA) *(XBAR-_THETA_ ); 
IF _WIL_ <= _CHI_ THEN WCONFO = WCONF0+1; 
IF mu <= _fcrit_ THEN MCONFO = MCONF0+1; 
*checking axis1; 
DO Z1 = rx1 TO MAXX1 BY RX1; 
z2 = o; 
THETA = Z1 // Z2; 
WIL (WILCOXON-_THETA_)'*INV(TAU_W)*( WILCOXON-_THETA_); 
_MU_ (XBAR-_THETA_) ' *INV(SIGMA)*(XBAR-_THETA_); 
IF _WIL_ <=_CHI_ THEN wf lag1=1; 
IF _mu_<= _fcrit_ THEN mflag1=1; 
END; 
*checking axis2; 
DO Z2 = rx2 TO MAXX2 BY RX2; 
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z1 = o; 
END; 
_THETA_= Z1 // Z2; 
WIL 
MU 
(WILCOXON-_THETA_)'*INV(TAU_W)*(WILCOXON-_THETA_); 
(XBAR-_THETA_)'*INV(SIGMA)*(XBAR -_THETA_); 
IF _WIL_ <=_CHI_ THEN wflag2=1; 
IF _mu_<= _fcrit_ THEN mflag2=1; 
if (wflag1=1)*(wflag2=1)=1 then wconf12=wconf12+1; 
if (wflag1=1)*(wflag2=0)=1 then wconf1=wconf1+1; 
if (wflag1=0)*(wflag2=1)=1 then wconf2=wconf2+1; 
if (wflag1=0)*(wflag2=0)=1 then wconfts=wconfts+1; 
if (mflag1=1)*(mflag2=1)=1 then mconf12=mconf12+1; 
if (mflag1=1)*(mflag2=0)=1 then mconf1=mconf1+1; 
if (mflag1=0)*(mflag2=1)=1 then mconf2=mconf2+1; 
if (mflag1=0)*(mflag2=0)=1 then mconfts=mconfts+1; 
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thersyn = thersyn I I (GROUP 11 SIMUL 11 wconfO 11 wconf1 11 wconf2 11 
wconf12 11 wconfts 11 mconfO 11 mconf1 11 
mconf2 11 mconf12 11 mconfts); 
LABEL TS {'GROUP' 'SIMUL' 'WCONFO' 'WCONF1 ' 'WCONF2' 'WCONF12' 
'WCONFTS' 
'MCONFO' 'MCONF1 ' 'MCONF2' 'MCONF12' 'MCON-
FTS'}; 
finish; 
START FORPLOT; 
* CRITICAL VALUE FROM CHI SQUARE DISTN WITH P OF, ALPHA=.05; 
_CHI_ = 5.99; 
ddf = nrow(x)-p; 
_F_= finv(.95,p,ddf); 
_fcrit (_num_-1)*p/{_num_-p)*_f_; 
MAXX1 = X[<>,1] + 5; 
MAXX2 = X[<>,2] + 5; 
RX1 = MAXX1/30; 
RX2 = MAXX2/30; 
WILCONF = WILCOXON' I I O; 
XBARCONF = XBAR' I I O; 
DO Z1 = 0 TO MAXX1 BY RX1; 
DO Z2 = 0 TO MAXX2 BY RX2; 
_THETA_= Z1 // Z2; 
_WIL_ = (WILCOXON-_THETA_)'*INV(TAU_W)*(WILCOXON-_THETA_); 
_MU_ = (XBAR-_THETA_)'*INV(SIGMA)*(XBAR-_THETA_); 
120 
IF WIL <= _CHI_ THEN WILCONF = WILCONF // (_THETA_' 11 _WIL_); 
IF MU <= _fcrit_ THEN XBARCONF= XBARCONF II (_THETA_' 11 
_MU_); 
END; 
END; 
LABEL = { 'X1 ' 'X2' 'VALUE'}; 
CREATE WILCONF FROM WILCONF[COLNAME=LABEL]; APPEND FROM WILCONF; 
CREATE XBARCONF FROM XBARCONF[COLNAME=LABEL]; APPEND FROM XBARCONF; 
FREE MEDCONF WILCONF WBARCONF; 
FINISH; 
START JOB; 
DO GROUP =1 TO 5; 
DO SIMUL = 1 TO 100; 
RUN SIMULATE; 
RUN IMPROVE; 
P=NROW(IN_PARMS); 
X = RESULTS[,2:P+1]; 
F=RESULTS[,P+7]; 
_num_=nrow(results); 
RUN RANK_LOC; 
RUN THERSYN; 
gvar_sig = det(var_xbar); 
gvar_w = det(var_wilc); 
LOC = LOC // (GROUP I I SIMUL I I TSTAR I I TSTRTEST I I PVALUE I I 
BSTAR 11 BSTRTEST 11 PVALUEB 11 tstar1a 11 tstrts1a 11 
bstar1 a 11 
bstrts1a 11 tstar1b 11 tstrts1b 11 bstar1b 11 bstrts1b 11 
tstar2a 11 tstrts2a 11 bstar2a 11 bstrts2a 11 tstar2b 11 
tst rts2b 11 bstar2b 11 bstrts2b); 
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FINLOC=FINLOC // (GROUP 11 SIMUL 11 WILCOXON' 11 GVAR_W 11 XBAR' 11 
GVAR_SIG 11 
median ' 11 respwlcx' 11 respxbar'); 
IF GROUP=1 THEN IF SIMUL=1 THEN RUN FORPLOT; 
IF GROUP=1 THEN IF SIMUL=1 THEN DO; 
CREATE RESULTS FROM RESULTS[COLNAME=RESLAB]; 
APPEND FROM RESULTS; 
END; 
free results; 
END; 
END; 
LABEL {'GROUP' 'SIMUL' 'TSTAR' 'TSTRTEST' ' PVALUEW' 
'BSTAR' 'BSTRTEST' ' PVALUEB' 'TSTAR1 a ' 'TSTRTS1 a' 'BSTAR1 a' 
'BSTRTS1a' 
'TSTAR1 b' 'TSTRTS1 b ' 'BSTAR1 b' 'BSTRTS1 b' 'TSTAR2a ' 
'TSTRTS2a' 'BSTAR2a' 
'BSTRTS2a' 'TSTAR2b' 'TSTRTS2b' 'BSTAR2b' 'BSTRTS2b '} ; 
FLABEL ={'GROUP' 'SIMUL' 'WIL1' 'WIL2' ' GVAR W' 'MU1' 'MU2' 
'GVAR SIG' 'MED1 ' 
'MED2' 'WIL_RESP' 'MU_RESP'}; 
CREATE LOC FROM LOC[COLNAME=LABEL]; 
APPEND FROM LOC; 
CREATE FINLOC FROM FINLOC[COLNAME=FLABEL]; 
APPEND FROM FINLOC; 
CREATE THERSYN FROM THERSYN[COLNAME=LABELTS]; 
APPEND FROM THERSYN; 
FINISH; 
RUN JOB; 
PROC SORT DATA=THERSYN; 
BY GROUP SIMUL; 
data thersyn; 
set the rsyn; by group; 
if l ast ,group; 
PROC PRINT DATA=THERSYN; 
title4 'Evaluation of Confidence Ellipsoid'; 
Proc Means data=thersyn mean n std; 
PROC SORT DATA=LOC; 
BY GROUP SIMUL; 
PROC MEANS SUM N data=loc; 
VAR TSTRTEST BSTRTEST tstrts1a bstrts1a tstrts1b bstrts1b 
tstrts2a bstrts2a tstrts2b bstrts2b; 
title4 'Number of Improved Responses'; 
proc summary data=finloc mean n var; 
va r WIL1 WIL2 MU1 MU2 MED1 MED2 WIL RESP MU_RESP; 
by group; 
output out=newfloc mean=; 
proc means data=newfloc mean n std; 
title4 'Summary of Final Locations and Final Response' ; 
PROC summary data=loc MEAN N va r ; 
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var tstar tst r t est bs t a r bstrtest tsta r 1a t strts1a bs t ar1a bstrts1a 
tstar1b tstrts1b bstar1b bstrts1b tstar2a tstrts2a bstar2a bstrts2a 
tstar2b tstrts2b bstar2b bstrts2b; 
BY GROUP; 
output out=newsumm mean=; 
proc means data=newsumm mean n std; 
title4 'TSTAR=Wilcoxon Sign Rank, BSTAR=Fisher Sign Test '; 
RUN; 
PROC GPLOT DATA=WILCONF; 
PLOT X1*X2 /HZERO VZERO ; 
label x1='HCTZ (pi lls )' x2='DLTZ (pills)'; 
TITLE4 
'ASYMPTOTIC CONFIDENCE REGION BASED ON THE WILCOXON SIGN-RANK STATIS -
TIC'; 
PROC GPLOT DATA=XBARCONF; 
PLOT X1*X2 / HZERO VZERO; 
l abel x1= 'HCTZ (pi lls )' x2=' DLTZ (pills ) ' ; 
TITLE4 
'ASYMPTOTIC CONFIDENCE REGION BASED ON THE ESTIMATED MEAN'; 
DATA RESULTS; 
SET RESULTS; 
IF FUNCTION=-9999999 THEN FUNCTION=.; 
proc print data=results; 
title4 ' '; 
proc means data=results; 
var FUNCTION DECR_BP CHG_cho CHG_glu; 
title4 'Summary of Final Responses'; 
proc freq data=results; 
tables x1*x2/noprint nocol norow nocum nopercent out=scatfreq; 
PROC GPLOT DATA=scatfreq; 
* SYMBOL1 V=STAR; 
PLOT X1*X2=count/VZERO HZERO; 
label x1='HCTZ (pills)' x2='DLTZ (pills)'; 
TITLE4 'Scatterplot of Final Locations'; 
run; 
proc g3d data=scatfreq; 
scatter x2*x1=count / xticknum=11 yticknum=20 zmin=O; 
label x1='HCTZ (pills)' x2='DLTZ (pills)'; 
title4 'Pyramid Plot of Final Locations'; 
run; 
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Program SIMPLEX 
START SIMPLEX; 
*********************************************************************** 
* This program in PROC !ML of SAS conducts the Nelder-Mead simplex 
* program for function minimization . The program is adapted from 
*Olsson (1974), Journal of Quality Technology 6, 53-57. 
* 
* The user needs to provide the module FUNCTION which contains the 
* 
* 
* 
* 
* 
* code for calculating the function given the set of parameters. For * 
* this module PARMS is the column K-vector of parameters and FN_VALUE * 
* is the function evaluated at PARMS. Also, the user needs to * 
* provide the column K-vectors of starting values IN_PARMS and * 
* initial step values IN STEPS when calling this module. * 
* * 
* There is no printed output that results from running this module. * 
* However, the column K-vector PARMS (the set of parameters which * 
*minimize the function), FN_VALUE (the function evaluated at PARMS), * 
* and COUNT (the number of iterations) are available to the user. * 
* 
* As a cautionary note, the user should not construct matrices in 
* PROC !ML with the naming convention _MATRIX_ because the modules 
* use this for all temporary matrices. 
* 
* 
* 
* 
**********************************************************************· 
' 
_EPS_=1 .OE-4;_K_=NROW(IN_PARMS);_KK_=_K_+1; 
_P_=J(_K_,_KK_,O);_Y_=J(1,_KK_,O); 
COUNT=O;_DABIT_=2.04607E-20;_BIGNUM_=1.0E38;_KONVGE_=5; 
_PBAR_=J(_K_,1,0);_PSTAR_=_PBAR_;_P2STAR_=_PBAR_; 
_RCOEFF_=1.0;_ECOEFF_=1.5;_CCOEFF_=0.5; 
**CONSTRUCT INITIAL SIMPLEX**; 
_P_[,_KK_]=IN_PARMS;PARMS=IN_PARMS;RUN FUNCTION;_A_=FN_VALUE; 
FO_VALUE=_A_; 
_Y_[_KK_]=_A_;COUNT=COUNT+1; *print count parms fO value 
DO I =1 TO _K_; 
_P_[,_I_]=IN_PARMS;_P_[_I_,_I_]=_P_[_I_,_I_]+IN_STEPS[_I_J; 
_TEMP_=_P_[,_I_J;PARMS=_TEMP_;RUN FUNCTION;_A_=FN_VALUE; 
_Y_[,_I_]=_A_;COUNT=COUNT+1; 
END; 
**SIMPLEX IS NOW CONSTRUCTED**; 
HILO: 
_YLO_=MIN(_Y_);_YNEWLO_=MAX(_Y_); 
DO _I_=1 TO _KK_; 
IF _Y_[,_I_]=_YLO_ THEN _ILO_=_I_; 
IF _Y_[,_I_]=_YNEWLO_ THEN IHI_=_I_; 
END; 
**PERFORM CONVERGENCE CHECK ON FUNCTION**; 
**THE RATIO OF THE LARGEST TO SMALLEST VERTEX FUNCTION TEST**; 
_DCHK_=(_YNEWLO_+_DABIT_)/(_YLO_+_DABIT_ )-1; 
IF ABS(_DCHK_)<_EPS_ THEN GOTO BEST; 
_KONVGE_=_KONVGE_-1; 
IF _KONVGE_=O THEN DO;_KONVGE_=5; 
DO _I_=1 TO _K_; 
_COORD1 _=_P_ [_I_ ,1]; _COORD2_=_COORD1_; 
DO _J_=2 TO _KK_; 
IF _P_[_I_,_J_]<_COORD1_ THEN _COORD1_=_P_[_I_,_J_]; 
IF _P_[_I_,_J_]>_COORD2_ THEN _COORD2_=_P_[_I_,_J_]; 
END; 
_DCHK_=(_COORD2_+_DABIT_)/(_COORD1_+_DABIT_)-1; 
END; 
END; 
IF ABS(_DCHK_)<=_EPS_ THEN GOTO BEST; 
if count>_niter_ then goto best; 
**CALCULATE _PBAR_ , THE CENTROID OF THE** ; 
**SIMPLEX VERTICES EXCEPTING THAT WITH Y VALUE 
DO I =1 TO _K_;_Z_=O; 
YNEWLO ** · 
- - ' 
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DO _J_=1 TO _KK_;_Z_=_Z_+_P_[_I_,_J_J;END ; 
_Z_=_Z_-_P_[_I_,_IHI_];_PBAR_[_I_]=_Z_/_K_; 
END; 
_PSTAR_=(1+_RCOEFF_)*_PBAR_-_RCOEFF_*_P_[,_IHI_J; 
**REFLECTION THROUGH THE CENTROID**; 
PARMS=_PSTAR_;RUN FUNCTION;_YSTAR_=FN_VALUE; 
COUNT=COUNT+1 ; *print 'reflection' count parms fn value 
IF COUNT >=_NITER_ THEN GOTO retain; 
IF _YSTAR_ >= YLO THEN GOTO NOEXT; 
**SUCCESSFUL REFLECTION, SO EXTENSION**; 
_P2STAR_=_ECOEFF_*_PSTAR_+(1-_ECOEFF_)*_PBAR_; 
PARMS=_P2STAR_; RUN FUNCTION;_Y2STAR_=FN_VALUE ; 
COUNT=COUNT+1; *print 'extension' count parms fn value 
**RETAIN EXTENSION OR CONTRACTION**; 
IF _Y2STAR_ >=_YSTAR_ THEN GOTO RETAIN; 
EXTCON: 
_P_[,_IHI_)=_P2STAR_; 
_Y_[_IHI_)=_Y2STAR_; 
GOTO HILO; 
**NO EXTENSION**; 
NOEXT: 
_L_=O; 
DO I =1 TO _KK_; 
IF _Y_ [_I_] >_YSTAR_ THEN 
END; 
IF L >1 THEN GOTO RETAIN; 
L = L +1 · 
- - - - ' 
**CONTRACTION ON THE REFLECTION SIDE OF THE CENTROID* *; 
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IF _L_=1 THEN DO; 
_P_[,_IHI_]=_PSTAR_; 
_Y_[_IHI_]=_YSTAR_; 
END; 
**CONTRACTION ON THE _Y_[_IHI_] SIDE OF THE CENTROID**; 
IF COUNT >= _NITER_ THEN GOTO BEST; 
_P2STAR_=_CCOEFF_*_P_[,_IHI_]+(-_CCOEFF_+1)*_PBAR_; 
PARMS=_P2STAR_ ;RUN FUNCTION;_Y2STAR_=FN_VALUE; 
COUNT=COUNT+1; *print 'contraction' count parms f n_value; 
IF COUNT>=_NITER THEN GOTO BEST; 
IF _Y2STAR_<_Y_[_IHI_] THEN GOTO EXTCON; 
**CONTRACT THE WHOLE SIMPLEX**; 
DO _J_=1 TO _KK_; 
DO _I_=1 TO _K_; 
_P_[_I_,_J_]=0.5*(_P_[_I_,_J_]+_P_[_I_,_ILO_]); 
END;_XMIN_=_P_[,_J_]; 
PARMS=_XMIN_;RUN FUNCTION;_A_=FN_VALUE;_Y_[ , _J_]=_A_; 
*print 'whole contraction' count parms fn value 
END; 
COUNT=COUNT+_KK_; 
IF COUNT>=_NITER_ THEN GOTO BEST; ELSE GOTO HILO; 
RETAIN: 
_P_ [,_IHI_]=_PSTAR_; _Y_ [_IHI_ ]=_YSTAR_;GOTO HILO; 
BEST: 
_YNEWLO_=_BIGNUM_; 
DO _J_=1 TO _KK_; 
IF _Y_ [_J_ ]<_YNEWLO_ THEN DO; 
_YNEWLO_=_Y_[ _J _ ];_IBEST_=_J _ ; 
END; 
END; 
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_Y_[_IBEST_]=_BIGNUM_;_YSEC_=_BIGNUM_; 
DO _J_=1 TO _KK_; 
IF _Y_[_J_)<_YSEC_ THEN DO; 
_YSEC_=_Y_[_J_];_ISEC_=_J_; 
END; 
END; 
_XMIN_=_P_[,_IBEST_];_XSEC_=_P_[,_ISEC_]; 
PARMS=round(_XMIN_); 
FN_VALUE=_YNEWLO_; 
FREE _EPS __ K __ KK __ P __ Y __ DABIT __ BIGNUM __ KONVGE_; 
FREE PBAR __ PSTAR P2STAR RCOEFF ECOEFF __ CCOEFF_; 
FREE _A __ I __ TEMP __ YLO __ YNEWLO __ ILO __ IHI_; 
FREE _DCHK __ COORD1 __ COORD2 __ z __ YSTAR __ L __ J_; 
FREE _XMIN __ IBEST __ YSEC __ XSEC_; 
FINISH; 
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Program RANK_LOC 
START RANK_LOC; 
N=NROW(X);P=NCOL(X); 
XBAR=X[+,]/N;XBAR=XBAR'; *print x; 
respxbar=F[+,]/N; respxbar=respxbar'; 
epsilon=0.25; 
SIGMA=((X'*X)-(N*XBAR*XBAR' )) /( N-1); 
VAR_XBAR=SIGMA/N; 
DO _!_=1 TON BY 1; 
_I1_=_I1_l IJ(1,N-_I_+1,_I_); 
_!2_ = _!2_ I I (_I_: N); 
END;FREE _I_; 
WILCOXON=J(P,1,0);MEDIAN=J(P,1,0); respwlcx=J(1,1,0); 
GAMMA_W=J(P,P,O);GAMMA_M=J(P,P,O); 
DO; _FWALSH_=(F[_I1_]+F[_I2_]) / 2; 
END; 
_FWTEMP_=_FWALSH_; 
_FWALSH_[RANK(_FWALSH_)]=_FWTEMP_; 
FREE _FWTEMP_; 
_FMID_=N#( N+1) /4; 
respwlcx=(_FWALSH_[_FMID_]+_FWALSH_[_FMID_+1]) /2 ; 
FREE _FMID __ FWALSH_; 
DO _J_=1 TOP BY 1; 
_WALSH_=(X[_I1 _ ,_J _ ]+X[_I2_,_J_])/2; 
_WTEMP_=_WALSH_; 
_WALSH_[RANK(_WALSH_),]=_WTEMP_; 
FREE _WTEMP_; 
_MID_=N#(N+1)/4; 
WILCOXON[_J_,]=(_WALSH_[ _M ID_,]+_WALSH_ [_MID_+1,]) /2 ; 
_A_=ROUND(_MID_ -0,5-(1.96#SQRT(N#(N+1) #((2#N)+1)/24))); 
_LENGTH_=(_WALSH_ [(N#( N+1) /2) -_A_,] - _WALSH_[_A_+1,]); 
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if _LENGTH_=O then _LENGTH_=2*epsilon; 
GAMMA_W[_J_,_J_]=(4#1.96) / (SQRT(12#N)#_LENGTH_); 
FREE _MID __ WALSH __ A __ LENGTH_; 
_XTEMP1_=X[,_J_J;_XTEMP2_=_XTEMP1_; 
_XTEMP1_[RANK(_XTEMP1_),]=_XTEMP2_; 
FREE _XTEMP2_; 
_MID_=N/2; 
IF MOD(N,2)=1 THEN MEDIAN[_J_,]=_XTEMP1_[(N+1)/2,]; 
ELSE MEDIAN[_J_,]=(_XTEMP1_[_MID_,]+_XTEMP1_[_MID_+1,]) / 2; 
_Q1 _=ROUND((N+1)/4);_Q3_=ROUND(3#(N+1) / 4); 
_IQR_=_XTEMP1_[_Q3_,]-_XTEMP1_[_Q1_,J;_HN_=_IQR_/SQRT(N) ; 
GAMMA_M[_J_,_J_]=2#SUM(ABS( MEDIAN[_J_,]-_XTEMP1_)<=_HN_) / (N#_HN_); 
FREE _MID __ XTEMP1 __ Q1 __ Q3 __ IQR __ HN_; 
END;FREE _J __ i1 __ i2_; 
NU_W=J(P,P,O);NU_M=J(P,P,O); 
DO _J1 _=1 TOP BY 1; 
_RANK1 _=RANKTIE(ABS(X[, _J1 _ ]-WILCOXON[ _J1 _ ,]))/(N+1); 
_SIGN1W_=(X[,_J1_]<=WILCOXON[_J1_,])-(X[,_J1_]>WILCOXON[_J1_, ]) ; 
_SIGN1M_=(X[,_J1_]<=MEDIAN[_J1_,])-(X[,_J1_]>MEDIAN[_J1_,]); 
DO _J2_=1 TO _J1_ BY 1; 
_RANK2_=RANKTIE(ABS(X[, _J2_]-WILCOXON[_J2_, ]))/(N+1); 
_SIGN2W_=(X[,_J2_]<=WILCOXON[_J2_,])-(X[,_J2_] >WILCOXON[ _J2_,J); 
_SIGN2M_=(X[,_J2_] <=MEDIAN[_J2_,])-( X[,_J2_]>MEDIAN[_J2_ , J); 
_T_=_SIGN1W_#_SIGN2W_; 
NU_W[_J1_,_J2_]=SUM(_RANK1_#_RANK2_#_T_) / N; 
NU_W[_J2_,_J1_]=NU_W[_J1_,_J2_J; 
_T_=_SIGN1M_#_SIGN2M_; 
NU_M[ _J1 _ ,_J2_]=SUM(_T_ ) / N; 
NU_M[_J2_ , _J1 _ ]=NU_M[ _J1 _ ,_J2_]; 
END; 
END; 
FREE _J1 _ _ J2 __ RANK1 __ RANK2 __ SIGN1W __ SIGN1 M __ SIGN2W_ SIGN2M _ _ T_; 
TAU_W=INV(GAMMA_W)*NU_W*INV(GAMMA_W); 
VAR_WILC=TAU_W/ N; 
FINISH; 
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